[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Microbiologics Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":239},{"warningLetters":4,"total":238},[5,32,55,76,99,121,146,166,182,201,221],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},248,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-16T04:00:00Z\">03\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrobiological-testing-consulting-llc-720374-03162026\">Microbiological Testing &amp; Consulting, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-53\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Lauren Szarzynski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Microbiological Testing &amp; Consulting, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5661 W. 120th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alsip\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lauren@mtcresearch.com\"> lauren@mtcresearch.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-53\u003C\u002Fp>\u003Cp>March 16, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Szarzynski:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Microbiological Testing &amp; Consulting, LLC, FEI 3003875820, at 5661 W. 120th Street, Alsip, from September 8 to 16, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your September 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.160(b) and 21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm is a contract testing laboratory that conducts testing of various application and nonapplication drug products for your customers. You failed to conduct appropriate testing to ensure that the results your firm provided to customers were accurate and scientifically sound.\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Adequate Documentation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm lacks significant CGMP documentation for your microbiological testing. For example, you routinely failed to document specific attributes of each test such as:\u003C\u002Fp>\u003Cul>\u003Cli>equipment number\u003C\u002Fli>\u003Cli>sample size\u003C\u002Fli>\u003Cli>media batch number\u003C\u002Fli>\u003Cli>sample dilutions\u003C\u002Fli>\u003Cli>incubation temperatures\u003C\u002Fli>\u003Cli>name\u002Fsignature of performing analyst\u003C\u002Fli>\u003C\u002Ful>\u003Cp>According to your personnel, your firm also lacked adequate equipment logs to track usage and maintenance.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to performing a comprehensive review of your testing operations and records. Based on the outcome of the review, your firm plans to update the affected data and test forms. You did not provide specific details on the records, equipment, and data that will be evaluated, nor did you commit to conducting a full retrospective review of test results provided to your customers.\u003C\u002Fp>\u003Cp>Additionally, you indicate that going forward you will meet standards for laboratory studies. Please note that appropriate regulatory requirements for laboratories conducting testing for drug product manufacturers are 21 CFR parts 210 and 211 and Section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Laboratory investigations cannot be performed when systems, procedures, and documentation are deficient.\u003C\u002Fp>\u003Cp>Complete and accurate records are necessary to ensure that test methods are consistently followed and reproducible. Additionally, complete test records are necessary to reliably conduct record reviews and adequately investigate deviations and drug product failures.\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Appropriate Media Qualification\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You lack adequate controls to ensure the reliability of your microbiological testing results. For example, the media used to test your customers drug products was inadequately qualified. You lacked screening for inhibitory properties of your incoming lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you commit to reviewing your tests and methods to identify gaps and implement the appropriate remediation.\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not commit to pausing testing until assessments are complete, nor did you implement any interim corrective actions. Furthermore, your firm did not provide a plan to re-assess results that have been communicated to customers.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, test results, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A retrospective risk assessment of gaps found in your growth media qualification and suitability testing practices over the past three years. Describe how these gaps will be remediated to ensure reliable microbial enumeration and appropriate identification of objectionable microorganisms.\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacks appropriate systems and procedures for quality oversight of laboratory testing, documentation, and investigations.\u003C\u002Fp>\u003Cp>As noted in the prior charge, your quality unit did not have adequate oversight of documentation, media qualification, and other critical microbiology laboratory programs. In addition, you lacked adequate systems for investigations and ensuring analyst competencies.\u003C\u002Fp>\u003Cp>Furthermore, your management stated that in the past two years your firm conducted only one product out-of-specification (OOS) investigation and one water out-of-limit (OOL) for total aerobic microbial count (TAMC) investigation. These two investigations were the only ones available for our investigator to review. However, records collected during an FDA inspection of one of your customers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, indicated that your firm reported several OOL for TAMC and objectionable microorganism results within the past two years. It appears that your firm did not make all requested OOS\u002FOOL test data available during the inspection.\u003C\u002Fp>\u003Cp>In your response, you commit to implement a multiphase OOS investigation methodology. Your response is inadequate. You did not commit to assessing previous OOS results to ensure the investigations were adequate.\u003C\u002Fp>\u003Cp>Be reminded that it is your responsibility to ensure all data and information provided are accurate, complete, and readily available for inspection. As a contract laboratory, you must comply with the CGMP regulations that apply to operations you perform, including, but not limited to, those that address the operations of your quality control unit, laboratory, investigation system, and documentation system.\u003C\u002Fp>\u003Cp>\u003Cem>Training Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your training program is inadequate. CGMP training is not regularly performed at your firm as required by your established procedure. During the inspection, you could not provide records of CGMP training.\u003C\u002Fp>\u003Cp>In your response, you state a consultant will assess your training procedure for general CGMP requirements and a suitable CGMP training program shall be developed.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide any immediate steps to address the training program to ensure all employees are adequately trained to complete CGMP activities. Nor do you commit to stop testing until employees can receive appropriate CGMP training.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOL\u002FOOS (including raw material, in-process, and release\u002Fstability testing) results for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOL\u002FOOS:\u003Cbr>o Provide a list of all OOS and OOL results that were not investigated and your corresponding corrective actions including a reassessment of all instances to determine any additional action needed related to nonconforming results.\u003Cbr>o For each OOL\u002FOOS include your CAPA and how you will ensure all OOS and OOL results will be investigated and communicated in a timely manner to your customer(s) on the certificate of analysis for appropriate follow up.\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOL\u002FOOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o An explanation for the discrepancy in the number of OOL and objectionable microorganism investigations that you provided to our investigator compared with the number that you provided to your customer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOL\u002FOOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Assurance that data, findings, and supporting documentation relating to any OOS\u002FOOL result are promptly conveyed to customers\u003Cbr>o Revised OOL\u002FOOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>A description of how top management supports quality assurance and reliable test operations including, but not limited to, timely provision of resources to proactively address emerging quality issues and to assure a continuing state of control.\u003C\u002Fli>\u003Cli>Documentation of training for all relevant personnel on revised policies, procedures, and other associated items.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003Cbr>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Responsibilities of Contract Testing Lab\u003C\u002Fstrong>\u003Cbr>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your customers. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm; you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003875820 and ATTN: Marva Taylor.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-53\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Lauren Szarzynski\n\nRecipient Title\n\nOwner\n\nMicrobiological Testing & Consulting, LLC\n\n5661 W. 120th Street\n\nAlsip, IL 60803\n\nUnited States\n\nlauren@mtcresearch.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-53\nMarch 16, 2026\nDear Ms. Szarzynski:\nThe United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Microbiological Testing & Consulting, LLC, FEI 3003875820, at 5661 W. 120th Street, Alsip, from September 8 to 16, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your September 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.160(b) and 21 CFR 211.165(b)).\nYour firm is a contract testing laboratory that conducts testing of various application and nonapplication drug products for your customers. You failed to conduct appropriate testing to ensure that the results your firm provided to customers were accurate and scientifically sound.\nLack of Adequate Documentation\nYour firm lacks significant CGMP documentation for your microbiological testing. For example, you routinely failed to document specific attributes of each test such as:\nequipment number\nsample size\nmedia batch number\nsample dilutions\nincubation temperatures\nname\u002Fsignature of performing analyst\nAccording to your personnel, your firm also lacked adequate equipment logs to track usage and maintenance.\nYour response is inadequate. You commit to performing a comprehensive review of your testing operations and records. Based on the outcome of the review, your firm plans to update the affected data and test forms. You did not provide specific details on the records, equipment, and data that will be evaluated, nor did you commit to conducting a full retrospective review of test results provided to your customers.\nAdditionally, you indicate that going forward you will meet standards for laboratory studies. Please note that appropriate regulatory requirements for laboratories conducting testing for drug product manufacturers are 21 CFR parts 210 and 211 and Section 501(a)(2)(B) of the FD&C Act.\nLaboratory investigations cannot be performed when systems, procedures, and documentation are deficient.\nComplete and accurate records are necessary to ensure that test methods are consistently followed and reproducible. Additionally, complete test records are necessary to reliably conduct record reviews and adequately investigate deviations and drug product failures.\nLack of Appropriate Media Qualification\nYou lack adequate controls to ensure the reliability of your microbiological testing results. For example, the media used to test your customers drug products was inadequately qualified. You lacked screening for inhibitory properties of your incoming lots of (b)(4).\nIn your response, you commit to reviewing your tests and methods to identify gaps and implement the appropriate remediation.\nYour response is inadequate because you did not commit to pausing testing until assessments are complete, nor did you implement any interim corrective actions. Furthermore, your firm did not provide a plan to re-assess results that have been communicated to customers.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, test results, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA retrospective risk assessment of gaps found in your growth media qualification and suitability testing practices over the past three years. Describe how these gaps will be remediated to ensure reliable microbial enumeration and appropriate identification of objectionable microorganisms.\nA complete assessment of documentation systems used throughout your laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm lacks appropriate systems and procedures for quality oversight of laboratory testing, documentation, and investigations.\nAs noted in the prior charge, your quality unit did not have adequate oversight of documentation, media qualification, and other critical microbiology laboratory programs. In addition, you lacked adequate systems for investigations and ensuring analyst competencies.\nFurthermore, your management stated that in the past two years your firm conducted only one product out-of-specification (OOS) investigation and one water out-of-limit (OOL) for total aerobic microbial count (TAMC) investigation. These two investigations were the only ones available for our investigator to review. However, records collected during an FDA inspection of one of your customers (b)(4), indicated that your firm reported several OOL for TAMC and objectionable microorganism results within the past two years. It appears that your firm did not make all requested OOS\u002FOOL test data available during the inspection.\nIn your response, you commit to implement a multiphase OOS investigation methodology. Your response is inadequate. You did not commit to assessing previous OOS results to ensure the investigations were adequate.\nBe reminded that it is your responsibility to ensure all data and information provided are accurate, complete, and readily available for inspection. As a contract laboratory, you must comply with the CGMP regulations that apply to operations you perform, including, but not limited to, those that address the operations of your quality control unit, laboratory, investigation system, and documentation system.\nTraining Program\nYour training program is inadequate. CGMP training is not regularly performed at your firm as required by your established procedure. During the inspection, you could not provide records of CGMP training.\nIn your response, you state a consultant will assess your training procedure for general CGMP requirements and a suitable CGMP training program shall be developed.\nYour response is inadequate. You do not provide any immediate steps to address the training program to ensure all employees are adequately trained to complete CGMP activities. Nor do you commit to stop testing until employees can receive appropriate CGMP training.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOL\u002FOOS (including raw material, in-process, and release\u002Fstability testing) results for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOL\u002FOOS:\no Provide a list of all OOS and OOL results that were not investigated and your corresponding corrective actions including a reassessment of all instances to determine any additional action needed related to nonconforming results.\no For each OOL\u002FOOS include your CAPA and how you will ensure all OOS and OOL results will be investigated and communicated in a timely manner to your customer(s) on the certificate of analysis for appropriate follow up.\no Determine whether the scientific justification and evidence relating to the invalidated OOL\u002FOOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no An explanation for the discrepancy in the number of OOL and objectionable microorganism investigations that you provided to our investigator compared with the number that you provided to your customer, (b)(4).\nA comprehensive review and remediation plan for your OOL\u002FOOS result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Adequate scoping of each investigation and its CAPA\no Assurance that data, findings, and supporting documentation relating to any OOS\u002FOOL result are promptly conveyed to customers\no Revised OOL\u002FOOS investigation procedures with these and other remediations\nA description of how top management supports quality assurance and reliable test operations including, but not limited to, timely provision of resources to proactively address emerging quality issues and to assure a continuing state of control.\nDocumentation of training for all relevant personnel on revised policies, procedures, and other associated items.\nData Integrity Remediation\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\nResponsibilities of Contract Testing Lab\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your customers. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm; you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003875820 and ATTN: Marva Taylor.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Microbiological Testing & Consulting, LLC","microbiological-testing-consulting-llc-720374-03162026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrobiological-testing-consulting-llc-720374-03162026","2026-10-26T08:09:24.793253+00:00","Warning Letter","Issued","2026-03-31","720374","Drugs","Ms. Lauren Szarzynski","2026-08-19T04:49:49.638+00:00","VIA EMAIL WITH READ RECEIPT","320-26-53","2026-03-16",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":53,"action_taken_date":54,"medical_device_id":19,"response_letter_date":19},1078,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2025-01-28T05:00:00Z\">01\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-17T05:00:00Z\">01\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchara-biologics-inc-698004-01172025\">Chara Biologics, Inc.\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","CGMP\u002FDeviations\u002FBiologics License Application (BLA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-25-698004\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joy Kong, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chara Biologics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9568 Topanga Canyon Blvd., Suite 104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chatsworth\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91311\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>January 17, 2025\u003C\u002Fp>\u003Cp>CBER 25-698004\u003C\u002Fp>\u003Cp>Dear Dr. Kong:&nbsp;\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, Chara Biologics, Inc., located at the above address, between July 23, 2024, and August 16, 2024. During the inspection, FDA documented that Chara Biologics, Inc. (“you”) manufactures and distributes a human amniotic fluid product, CharaExo, as well as cellular products derived from human umbilical cord, CharaCore and CharaOmni, for allogeneic use (collectively, “your products”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>&nbsp;\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Your firm is responsible for ensuring that your products comply with CGMP requirements regardless of who manufactures, processes, packs, or holds them. This letter also explains you are in violation of current good tissue practice (CGTP) requirements set forth in 21 CFR part 1271 in the manufacture of your CharaCore and CharaOmni products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Furthermore, CharaExo is also misbranded under sections 502(a) of the FD&amp;C Act, 21 U.S.C. § 352(a). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans. For example:\u003C\u002Fp>\u003Cp>• CharaExo\u003Cbr>&nbsp; o Chara Biologics’ brochure, “Let the Joy of Healing Begin,” tells prospective customers to choose its products because “Chara offers the most comprehensive stem cell product CharaCore and high potency growth factor\u002Fextracellular vesicle product CharaExo.” It explains that “stem cells have been shown to have clinical benefits in” a long list of conditions including various autoimmune disorders, “neurodegenerative conditions (Parkinson’s, Alzheimers, Multiple Sclerosis, ALS, etc.)”, diabetes, cardiovascular and lung diseases, autism, spinal cord injuries, and cirrhosis. It also explains stem cell treatment can benefit its audience by reducing inflammation, improving immune function, and enhancing tissue repair.\u003Cbr>&nbsp; o AAICT “Exosome Protocols” provide sample CharaExo dosing for the following diseases or conditions: Infertility, Osteoporosis, Diabetes, Autism, Cardiac, Renal, Hepatic, Pulmonary conditions, etc…. Musculoskeletal…Shoulder\u002FHip\u002FKnees…Ligaments\u002FTendons\u002FMeniscus \u002FLabrum… Elbow\u002FWrist\u002FAnkle\u002FFingers… Spine…Erectile Dysfunction… Female Urinary Incontinence…Autoimmune Diseases… Neuropathy… CNS Disease… Wound, Ulcers &amp; Burns…” These protocols, which are part of AAICT’s Fundamentals of Stem Cell Practice course, accompany Chara Biologics’ CharaExo products when Chara Biologics sells them to physicians as part of Starter Package 3.\u003Cbr>&nbsp; o Chara Biologics’ “FAQs for Physicians,” which you said you provide all your purchasing physicians, explains: “CharaExo also contains larger extracellular vesicles, as well as concentrated growth factors from amniotic fluid… Extracellular vesicles contain proteins, microRNAs and lipids, and all eukaryotic cells secrete and take up these nanoparticles, and they are a means of communication between cells. These nanoparticles have been increasingly recognized as playing an important role as the mediator of many of the MSC-associated therapeutic benefits. They can be quite useful therapeutically, as they may elicit a more immediate therapeutic response, although the benefits tend to be shorter-lasting than that of cell therapy.”\u003C\u002Fp>\u003Cp>• CharaCore\u003Cbr>&nbsp; o Statements in Chara Biologics’ “Let the Joy of Healing Begin” brochure (discussed above)\u003Cbr>&nbsp; o Chara Biologics’ FAQ for Physicians includes the following statements:\u003Cbr>&nbsp; &nbsp;  “CharaCore® is highly rich in MSC’s…MSC’s: have anti-microbial properties, helpful in fighting acute, chronic or systemic infections… shown to be effective against protozoa (as in Lyme disease)”\u003Cbr>&nbsp; &nbsp;  “How Can CharaCore help my patients? REGULATE INFLAMMATION, SCARRING &amp; PAIN Birth tissue products have been shown to reduce inflammation, fibrous tissue growth, and potential scar tissue formation.”\u003Cbr>&nbsp; &nbsp;  “How Can CharaCore help my patients? ANTI-MICROBIAL Application of birth tissue products has been shown to reduce bacteria counts in the wound…”\u003C\u002Fp>\u003Cp>• CharaOmni\u003Cbr>&nbsp; o Chara Biologics’ FAQ for Physicians and CharaOmni promotional brochure state: “[W]hat set[s] CharaOmni apart from all other skincare products on the market: 1) Regenerative Stem Cell Components… Wharton’s Jelly Extract… reduces scar formation, and enhances wound healing…. Amniotic Extracellular Matrix - possesses powerful anti-inflammatory...properties.”\u003Cbr>&nbsp; o Your website at www.charaomni.com explains “The stem cell regenerative elements in CharaOmni… have been known to provide crucial and powerful growth factors, extracellular matrix, as well as other cell signaling molecules that highly beneficial in skin repair and regeneration.”\u003C\u002Fp>\u003Cp>• Chara Biologics also promotes its products for the following diseases at www.charabiologics.com\u002Fscience, which links to https:\u002F\u002Faaict.org\u002Fclinical-evidence\u002F:\u003Cbr>&nbsp; o “…Alzheimer’s…Asthma…Autism…Chronic Pain…COPD…Crohn’s Disease…Degenerative Disc Disease…Heart Disease…Kidney Failure…Liver Cirrhosis…Lupus…Macular Degeneration…Migraines &amp; Tension Headache…Multiple Sclerosis…Nerve Injury…Osteoarthritis… Osteoporosis…Parkinson’s…”\u003C\u002Fp>\u003Cp>Therefore, CharaExo, CharaCore, and CharaOmni are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your CharaCore and CharaOmni products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Chara Biologics, Inc. does not qualify for any exception in 21 CFR 1271.15, and your CharaCore and CharaOmni products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your CharaCore and CharaOmni products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into a flowable form significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your CharaCore and CharaOmni products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). These products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, these products are intended for use in the treatment of a number of diseases and conditions listed above, which are not basic functions of umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your CharaCore and CharaOmni products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA, nor is there an investigational new drug application (IND) in effect for any of them.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP and\u002For CGTP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspection of your facility documented evidence of significant CGMP and CGTP violations. At the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA also identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\u003C\u002Fp>\u003Cp>The violations applicable to your products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish a quality unit with the responsibility and authority to approve or reject all labeling and drug products, and the responsibilities and procedures applicable to the quality control unit are not in writing and followed, as required by 21 CFR 211.22(a) and 211.22(d).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm is a manufacturer subject to CGMP requirements. See 21 CFR 210.3(b)(12). For example, at the time of the inspection, your firm relabeled, stored, and distributed CharaCore and stored and distributed CharaOmni.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>An adequate quality unit overseeing all elements of CGMP is necessary to ensure drug products are consistently manufactured in compliance with CGMP and meet established specifications for identity, strength, quality and purity. However, your firm does not receive documentation, such as production records or test results, for each lot received for approval or rejection by your firm before distribution. Additionally, your firm has not established responsibilities and procedures applicable to the quality unit such as the following:\u003C\u002Fp>\u003Cp>a. Laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b))\u003Cbr>b. Written procedures for production and process control designed to assure drug products have the identity, strength, quality, and purity purported or represented to possess (21 CFR 211.100(a))\u003Cbr>c. Review and approval of drug product production and control records, including those for packaging and labeling, to determine compliance with all established, approved written procedures before a batch is released or distributed (21 CFR 211.192)\u003Cbr>d. Written procedures describing the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a))\u003Cbr>e. Written procedures designed to assure that correct labels, labeling, and packaging are used (21 CFR 211.130)\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Documentation of the donor-eligibility determination, including the name of the responsible person who made the determination and the date of the determination, was not maintained, as required by 21 CFR 1271.55(d)(1)(iii).\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\u003Cp>Specifically, Chara did not maintain documentation of the donor eligibility determination, including the name of the responsible person who made the determination and the date of the determination, for donors of umbilical cord. Umbilical cord is used to manufacture CharaCore, which is used to manufacture CharaOmni.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranding Violation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your CharaExo product is also misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. § 352(a), because your labeling is false or misleading. Specifically, your firm extended the manufacturer’s expiration date for CharaExo lots by one year or more without supporting data. This false or misleading representation about your CharaExo product on your labeling causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. § 352(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your responses, received on September 1, 2024 and December 23, 2024,\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> to FDA’s Form FDA-483 in detail. Your responses are inadequate to address the violations noted above and on the Form FDA-483. While you assert that your products were manufactured according to section 361 of the PHS Act, the evidence collected shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act.\u003C\u002Fp>\u003Cp>We acknowledge that you state in your September and December 2024 responses that, “Chara Biologics is not [now], nor has it ever been a Stem Cell processor\u002Fmanufacturer.” We also acknowledge that you state in your December 2024 response that an agreement has been made with “the manufacturers to label all products prior to coming into the building.” Be advised that manufacture, processing, packing, or holding of a drug product includes packaging and labeling operations, testing, and quality control of drug products. See 21 CFR 210.3(b)(12)\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and 1271.3(e). Based on your responses, it appears that Chara continues to package, store, and distribute drug products. For the reasons described above, Chara Biologics is a manufacturer subject to applicable CGMP requirements. This is consistent with your signed affidavit from the inspection, in which you state, “Chara Biologics, Inc. – This is the primary manufacturing entity for the Chara products CharaCore, CharaExo and CharaOmni.”\u003C\u002Fp>\u003Cp>Be advised that Chara is responsible for ensuring its products are manufactured in compliance with CGMP. Drugs not manufactured in compliance with CGMP are adulterated. The FD&amp;C Act prohibits any person from introducing or delivering for introduction an adulterated or misbranded drug into interstate commerce.\u003C\u002Fp>\u003Cp>We refer you to the following document for additional information, \u003Cem>Guidance for Industry: Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> (November 2016), found at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry. Also, be advised that, under the CGMP regulations, a “quality control unit shall be responsible for approving or rejecting drug products manufactured, processed, packed, or held under contract by another company.” 21 CFR 211.22(a).\u003C\u002Fp>\u003Cp>With respect to donor eligibility, you state in your response that your contract manufacturers determine donor eligibility for the HCT\u002FPs used for your products. However, you are required to retain the donor-eligibility determination of the tissue donors for products that remain in inventory at your facility or have been distributed and remain in the marketplace as required by 21 CFR 1271.55(d)(1)(iii).\u003C\u002Fp>\u003Cp>Your responses do not adequately address the status of your manufacturing and distribution operations or your specific plans for disposition of the inventory of CharaExo, CharaCore, and CharaOmni at your facility that were manufactured under the conditions described in this letter. This includes the disposition of finished product received from your contract manufacturers prior to being re-labeled by your firm. Further, your responses do not adequately describe actions you have taken or plan to take to address the impact of the above-described deficiencies on your distributed products that remain in the marketplace. Your responses do not address your failure to have an IND in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products. Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>FDA has previously provided notice to you in a letter dated November 25, 2019, that based on a review of your website it appeared your firm was marketing a biological drug product (CharaCore) that does not qualify for any exception under 21 CFR 1271.15, as is also explained in this letter. Your response dated December 17, 2019, stated that you would remove all testimonials from your websites. However, a review of your various social media accounts, which are linked to your websites, revealed patient testimonials for Chara Biologics that describe treatment of various diseases and conditions. In addition, your March 13, 2020, response stated your intention to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, however your products are not the subject of an approved BLA, nor is there an IND in effect for any of them.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>We note that in addition to Chara Biologics, Inc., Dr. Kong also controls the American Academy of Integrative Cell Therapy, Inc. (AAICT), co-located at the same business address. These entities function together: Chara Biologics contracts with manufacturers to make its products, which Chara Biologics then relabels and distributes; and AAICT develops trainings, and training materials and protocols for Chara Biologics products, which are distributed with the products themselves.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that your amniotic fluid product, CharaExo, is not an HCT\u002FP because amniotic fluid is a secreted bodily fluid and the definition of HCT\u002FPs in 21 CFR 1271.3(d)(3) excludes secreted or extracted human products.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Because CharaCore and CharaOmni fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Manufacture, processing, packing, or holding of a drug product includes packaging and labeling operations, testing, and quality control of drug products per 21 CFR 210.3(b)(12).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your written responses are dated August 26, 2024, October 14, 2024, November 13, 2024, and December 18, 2024.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See footnote 4.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER-25-698004\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoy Kong, M.D.\n\nRecipient Title\n\nChief Executive Officer\n\nChara Biologics, Inc.\n\n9568 Topanga Canyon Blvd., Suite 104\n\nChatsworth, CA 91311\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nJanuary 17, 2025\nCBER 25-698004\nDear Dr. Kong:\nThe United States Food and Drug Administration (FDA) inspected your facility, Chara Biologics, Inc., located at the above address, between July 23, 2024, and August 16, 2024. During the inspection, FDA documented that Chara Biologics, Inc. (“you”) manufactures and distributes a human amniotic fluid product, CharaExo, as well as cellular products derived from human umbilical cord, CharaCore and CharaOmni, for allogeneic use (collectively, “your products”).1\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Your firm is responsible for ensuring that your products comply with CGMP requirements regardless of who manufactures, processes, packs, or holds them. This letter also explains you are in violation of current good tissue practice (CGTP) requirements set forth in 21 CFR part 1271 in the manufacture of your CharaCore and CharaOmni products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Furthermore, CharaExo is also misbranded under sections 502(a) of the FD&C Act, 21 U.S.C. § 352(a). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans. For example:\n• CharaExo\no Chara Biologics’ brochure, “Let the Joy of Healing Begin,” tells prospective customers to choose its products because “Chara offers the most comprehensive stem cell product CharaCore and high potency growth factor\u002Fextracellular vesicle product CharaExo.” It explains that “stem cells have been shown to have clinical benefits in” a long list of conditions including various autoimmune disorders, “neurodegenerative conditions (Parkinson’s, Alzheimers, Multiple Sclerosis, ALS, etc.)”, diabetes, cardiovascular and lung diseases, autism, spinal cord injuries, and cirrhosis. It also explains stem cell treatment can benefit its audience by reducing inflammation, improving immune function, and enhancing tissue repair.\no AAICT “Exosome Protocols” provide sample CharaExo dosing for the following diseases or conditions: Infertility, Osteoporosis, Diabetes, Autism, Cardiac, Renal, Hepatic, Pulmonary conditions, etc…. Musculoskeletal…Shoulder\u002FHip\u002FKnees…Ligaments\u002FTendons\u002FMeniscus \u002FLabrum… Elbow\u002FWrist\u002FAnkle\u002FFingers… Spine…Erectile Dysfunction… Female Urinary Incontinence…Autoimmune Diseases… Neuropathy… CNS Disease… Wound, Ulcers & Burns…” These protocols, which are part of AAICT’s Fundamentals of Stem Cell Practice course, accompany Chara Biologics’ CharaExo products when Chara Biologics sells them to physicians as part of Starter Package 3.\no Chara Biologics’ “FAQs for Physicians,” which you said you provide all your purchasing physicians, explains: “CharaExo also contains larger extracellular vesicles, as well as concentrated growth factors from amniotic fluid… Extracellular vesicles contain proteins, microRNAs and lipids, and all eukaryotic cells secrete and take up these nanoparticles, and they are a means of communication between cells. These nanoparticles have been increasingly recognized as playing an important role as the mediator of many of the MSC-associated therapeutic benefits. They can be quite useful therapeutically, as they may elicit a more immediate therapeutic response, although the benefits tend to be shorter-lasting than that of cell therapy.”\n• CharaCore\no Statements in Chara Biologics’ “Let the Joy of Healing Begin” brochure (discussed above)\no Chara Biologics’ FAQ for Physicians includes the following statements:\n “CharaCore® is highly rich in MSC’s…MSC’s: have anti-microbial properties, helpful in fighting acute, chronic or systemic infections… shown to be effective against protozoa (as in Lyme disease)”\n “How Can CharaCore help my patients? REGULATE INFLAMMATION, SCARRING & PAIN Birth tissue products have been shown to reduce inflammation, fibrous tissue growth, and potential scar tissue formation.”\n “How Can CharaCore help my patients? ANTI-MICROBIAL Application of birth tissue products has been shown to reduce bacteria counts in the wound…”\n• CharaOmni\no Chara Biologics’ FAQ for Physicians and CharaOmni promotional brochure state: “[W]hat set[s] CharaOmni apart from all other skincare products on the market: 1) Regenerative Stem Cell Components… Wharton’s Jelly Extract… reduces scar formation, and enhances wound healing…. Amniotic Extracellular Matrix - possesses powerful anti-inflammatory...properties.”\no Your website at www.charaomni.com explains “The stem cell regenerative elements in CharaOmni… have been known to provide crucial and powerful growth factors, extracellular matrix, as well as other cell signaling molecules that highly beneficial in skin repair and regeneration.”\n• Chara Biologics also promotes its products for the following diseases at www.charabiologics.com\u002Fscience, which links to https:\u002F\u002Faaict.org\u002Fclinical-evidence\u002F:\no “…Alzheimer’s…Asthma…Autism…Chronic Pain…COPD…Crohn’s Disease…Degenerative Disc Disease…Heart Disease…Kidney Failure…Liver Cirrhosis…Lupus…Macular Degeneration…Migraines & Tension Headache…Multiple Sclerosis…Nerve Injury…Osteoarthritis… Osteoporosis…Parkinson’s…”\nTherefore, CharaExo, CharaCore, and CharaOmni are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour CharaCore and CharaOmni products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264.2 HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Chara Biologics, Inc. does not qualify for any exception in 21 CFR 1271.15, and your CharaCore and CharaOmni products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your CharaCore and CharaOmni products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into a flowable form significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your CharaCore and CharaOmni products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). These products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, these products are intended for use in the treatment of a number of diseases and conditions listed above, which are not basic functions of umbilical cord in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.3 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your CharaCore and CharaOmni products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA, nor is there an investigational new drug application (IND) in effect for any of them.\nCGMP and\u002For CGTP Violations\nFDA’s inspection of your facility documented evidence of significant CGMP and CGTP violations. At the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA also identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\nThe violations applicable to your products include, but are not limited to, the following:\n1. Your firm failed to establish a quality unit with the responsibility and authority to approve or reject all labeling and drug products, and the responsibilities and procedures applicable to the quality control unit are not in writing and followed, as required by 21 CFR 211.22(a) and 211.22(d).\nYour firm is a manufacturer subject to CGMP requirements. See 21 CFR 210.3(b)(12). For example, at the time of the inspection, your firm relabeled, stored, and distributed CharaCore and stored and distributed CharaOmni.4\nAn adequate quality unit overseeing all elements of CGMP is necessary to ensure drug products are consistently manufactured in compliance with CGMP and meet established specifications for identity, strength, quality and purity. However, your firm does not receive documentation, such as production records or test results, for each lot received for approval or rejection by your firm before distribution. Additionally, your firm has not established responsibilities and procedures applicable to the quality unit such as the following:\na. Laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b))\nb. Written procedures for production and process control designed to assure drug products have the identity, strength, quality, and purity purported or represented to possess (21 CFR 211.100(a))\nc. Review and approval of drug product production and control records, including those for packaging and labeling, to determine compliance with all established, approved written procedures before a batch is released or distributed (21 CFR 211.192)\nd. Written procedures describing the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a))\ne. Written procedures designed to assure that correct labels, labeling, and packaging are used (21 CFR 211.130)\n2. Documentation of the donor-eligibility determination, including the name of the responsible person who made the determination and the date of the determination, was not maintained, as required by 21 CFR 1271.55(d)(1)(iii).\nSpecifically, Chara did not maintain documentation of the donor eligibility determination, including the name of the responsible person who made the determination and the date of the determination, for donors of umbilical cord. Umbilical cord is used to manufacture CharaCore, which is used to manufacture CharaOmni.\nMisbranding Violation\nYour CharaExo product is also misbranded under section 502(a) of the FD&C Act, 21 U.S.C. § 352(a), because your labeling is false or misleading. Specifically, your firm extended the manufacturer’s expiration date for CharaExo lots by one year or more without supporting data. This false or misleading representation about your CharaExo product on your labeling causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. § 352(a).\nResponse to the Form FDA-483\nWe have reviewed your responses, received on September 1, 2024 and December 23, 2024,5 to FDA’s Form FDA-483 in detail. Your responses are inadequate to address the violations noted above and on the Form FDA-483. While you assert that your products were manufactured according to section 361 of the PHS Act, the evidence collected shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act.\nWe acknowledge that you state in your September and December 2024 responses that, “Chara Biologics is not [now], nor has it ever been a Stem Cell processor\u002Fmanufacturer.” We also acknowledge that you state in your December 2024 response that an agreement has been made with “the manufacturers to label all products prior to coming into the building.” Be advised that manufacture, processing, packing, or holding of a drug product includes packaging and labeling operations, testing, and quality control of drug products. See 21 CFR 210.3(b)(12)6 and 1271.3(e). Based on your responses, it appears that Chara continues to package, store, and distribute drug products. For the reasons described above, Chara Biologics is a manufacturer subject to applicable CGMP requirements. This is consistent with your signed affidavit from the inspection, in which you state, “Chara Biologics, Inc. – This is the primary manufacturing entity for the Chara products CharaCore, CharaExo and CharaOmni.”\nBe advised that Chara is responsible for ensuring its products are manufactured in compliance with CGMP. Drugs not manufactured in compliance with CGMP are adulterated. The FD&C Act prohibits any person from introducing or delivering for introduction an adulterated or misbranded drug into interstate commerce.\nWe refer you to the following document for additional information, Guidance for Industry: Contract Manufacturing Arrangements for Drugs: Quality Agreements (November 2016), found at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry. Also, be advised that, under the CGMP regulations, a “quality control unit shall be responsible for approving or rejecting drug products manufactured, processed, packed, or held under contract by another company.” 21 CFR 211.22(a).\nWith respect to donor eligibility, you state in your response that your contract manufacturers determine donor eligibility for the HCT\u002FPs used for your products. However, you are required to retain the donor-eligibility determination of the tissue donors for products that remain in inventory at your facility or have been distributed and remain in the marketplace as required by 21 CFR 1271.55(d)(1)(iii).\nYour responses do not adequately address the status of your manufacturing and distribution operations or your specific plans for disposition of the inventory of CharaExo, CharaCore, and CharaOmni at your facility that were manufactured under the conditions described in this letter. This includes the disposition of finished product received from your contract manufacturers prior to being re-labeled by your firm. Further, your responses do not adequately describe actions you have taken or plan to take to address the impact of the above-described deficiencies on your distributed products that remain in the marketplace. Your responses do not address your failure to have an IND in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products. Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nFDA has previously provided notice to you in a letter dated November 25, 2019, that based on a review of your website it appeared your firm was marketing a biological drug product (CharaCore) that does not qualify for any exception under 21 CFR 1271.15, as is also explained in this letter. Your response dated December 17, 2019, stated that you would remove all testimonials from your websites. However, a review of your various social media accounts, which are linked to your websites, revealed patient testimonials for Chara Biologics that describe treatment of various diseases and conditions. In addition, your March 13, 2020, response stated your intention to (b)(4), however your products are not the subject of an approved BLA, nor is there an IND in effect for any of them.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n_________________________\n1 We note that in addition to Chara Biologics, Inc., Dr. Kong also controls the American Academy of Integrative Cell Therapy, Inc. (AAICT), co-located at the same business address. These entities function together: Chara Biologics contracts with manufacturers to make its products, which Chara Biologics then relabels and distributes; and AAICT develops trainings, and training materials and protocols for Chara Biologics products, which are distributed with the products themselves.\n2 We note that your amniotic fluid product, CharaExo, is not an HCT\u002FP because amniotic fluid is a secreted bodily fluid and the definition of HCT\u002FPs in 21 CFR 1271.3(d)(3) excludes secreted or extracted human products.\n3 Because CharaCore and CharaOmni fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all criteria in 21 CFR 1271.10(a).\n4 Manufacture, processing, packing, or holding of a drug product includes packaging and labeling operations, testing, and quality control of drug products per 21 CFR 210.3(b)(12).\n5 Your written responses are dated August 26, 2024, October 14, 2024, November 13, 2024, and December 18, 2024.\n6 See footnote 4.","Chara Biologics, Inc.","chara-biologics-inc-698004-01172025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchara-biologics-inc-698004-01172025","2026-10-26T08:08:13.826296+00:00","2025-01-28","698004","Biologics","Joy Kong, M.D.","2026-08-19T17:03:19.707+00:00","VIA UPS and Electronic Mail","CBER-25-698004","2025-01-17",{"id":56,"raw":57,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":18,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":61,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},252,[58,59,60,61,62,13,13,13],"\u003Ctime datetime=\"2026-03-24T04:00:00Z\">03\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-24T05:00:00Z\">02\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fisotis-orthobiologics-inc-723370-02242026\">IsoTis OrthoBiologics, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Peter P. Nalbach\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President and General Manager of Spine Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>IsoTis OrthoBiologics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2 Goodyear, Ste A,\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>CMS #723370\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 24, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Nalbach:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Irvine, CA from October 6, 2025, through October 17, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures resorbable calcium salt bone void filler devices, branded under the Accell Family of products, to include the Accell Evo3c. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, your manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from your Director Quality Systems, dated November 7, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\u003Cp>Your firm failed to adequately take action to correct the cause of nonconformities in order to prevent recurrence. Your firm's corrective and preventative action procedure, Corrective and Preventive Actions CP-1001 Rev. J Effective: 8\u002F22\u002F2022, requires your firm to perform an investigation, determine the need for containment, and assess the risk associated with the issue.\u003C\u002Fp>\u003Cp>Your firm opened CAPA 157738 on 7\u002F27\u002F23 to address potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination occurring during the demineralization process of bone tissue, due to the propeller blade contacting the bottom of the demineralization vessel. The issue was discovered by a manufacturing engineer and documented in emails dating back to 06\u002F22\u002F2023.\u003C\u002Fp>\u003Cp>As part of CAPA 157738, your firm conducted a risk assessment for the demineralization process. In your risk analysis document, PFMEA-011 Rev. 12, effective October 23, 2023, your firm identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a risk for particulate contamination. This risk was assigned a severity rating of Moderate and a probability of Improbable, resulting in an overall Acceptable risk rating. Despite discovering that the propeller blade was potentially shedding \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles during demineralization, your firm did not investigate whether this finding affected your risk probability rating. In CAPA 157738, your firm classified the risk as low without providing justification for this conclusion and determined that containment action was not required due to your determined low risk. Your firm's CAPA investigation and actions are inadequate because it did not assess the potential impact to finished devices, including distributed product.\u003C\u002Fp>\u003Cp>Additionally, your firm’s Verification of Effectiveness included reviewing 18 work orders to confirm that visual inspection of the propeller was performed. The verification of effectiveness does not demonstrate that visual inspection of the propeller is sufficient to identify potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate in your firm's demineralized bone matrix (DBM). Your firm did not verify if the corrective actions performed were sufficient to correct the potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination.\u003C\u002Fp>\u003Cp>Your firm closed CAPA 157738 on 12\u002F17\u002F2024 without evidence that \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination was no longer occurring during your demineralization process.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. While your firm’s response acknowledges procedural deficiencies and proposes process improvements, the CAPA defers critical product risk elements to separate CAPAs without clear indication that all deficiencies identified in CAPA-157738 have been adequately addressed. For example, in HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong>, your firm identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints determined to be relevant now that \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination has been identified as a potential contributing factor. However, none of the related CAPAs indicate whether an MDR assessment was performed for these complaints.\u003C\u002Fp>\u003Cp>Additionally, it is not clear why the scope of the CAPA retrospective review is from 01\u002F01\u002F2022 to present.\u003C\u002Fp>\u003Cp>2. Failure to revalidate a validated process when changes or process deviations occurred, as required by 21 CFR 820.75(c). For example:\u003C\u002Fp>\u003Cp>Your firm’s procedure, Validation Program QA-035 Effective: 6\u002F11\u002F21, requires revalidation for previously validated process parameters, component changes, and major design changes; however, your firm did not revalidate your demineralization press when a major design change was made.\u003C\u002Fp>\u003Cp>Your firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding that during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating the potential shedding of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates. Two corrective actions were implemented:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm updated TL-0091 for the Demineralization Press in design change order (DCO), DCO 6306 Released: 5\u002F24\u002F24, which changed the equipment design by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm determined that qualification or validation is not required, though the DCO describes the change category as Major. Your firm answered No to the question: Is there a change in the manufacturing equipment while maintaining the existing process? on your Form CPF-0302-001 Decision Tree, although your firm changed the equipment design by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm’s Director of Quality Systems and Assurance told the investigator that they considered the demineralization press to be a tool and not equipment.\u003C\u002Fp>\u003Cp>Additionally, your firm determined that \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection was sufficient to identify potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants and required training of your demineralization team to \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspect the propellers, however your firm has not validated the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection process for the propeller blades to demonstrate it is sufficient in identifying potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants in your firm’s demineralized bone matrix (DBM). In an email from your firm’s manufacturing engineer, they note that \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates are \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address production and process related deficiencies identified in Observation 2. Actions include validating the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection method with \u003Cstrong>(b)(4)\u003C\u002Fstrong> study, completing Installation Qualification for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> demineralization assemblies, and establishing preventative maintenance and calibration programs. However, while your firm validated the inspection method and qualified equipment, there is no objective evidence that:\u003C\u002Fp>\u003Cul>\u003Cli>An evaluation of the existing process validation was conducted to determine if the changes to the demineralization assemblies could impact the applicability of the existing Operational and Performance Qualifications.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination is no longer occurring in production and that the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\" clearance is sufficient to prevent all contact under all operating conditions\u003C\u002Fli>\u003Cli>Testing has been performed to confirm absence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles in DBM\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Furthermore, the verification of effectiveness plan measures compliance to procedures and execution of preventative maintenance but does not include testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates in finished product.\u003C\u002Fp>\u003Cp>Additionally, it is not clear why the scope identified in CAPA-100520 for reviewing tooling changes is January 2022 to present, when the affected timeframe extends back to 2008.\u003C\u002Fp>\u003Cp>3. Failure to establish an adequate risk analysis, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>Your firm’s procedure, CP-0305 Risk Management Rev. J1 Effective: 5\u002F27\u002F22, requires in Section 6.26.2 Perform Risk Reassessment (As Necessary), that if new or updated risk information is identified, it will be fed back into the risk management system and documented via update and approval of the appropriate risk management forms (such as the Hazard Analysis or FMEA).\u003C\u002Fp>\u003Cp>Your firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding, during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating potential shedding of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates. The CAPA identified the risk in PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II as \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Supplier error leading to particulate contamination resulting in transient inflammation, which defined a severity of Moderate and a probability occurrence of Improbable, and the Risk Acceptability as Acceptable.\u003C\u002Fp>\u003Cp>Your firm identified the propeller blade was potentially shedding \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates during the demineralization process; however, your firm did not update PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II to identify this new risk factor. \u003Cstrong>(b)(4)\u003C\u002Fstrong> only addresses potential contaminants from your supplier resulting in transient inflammation and does not address the risk of contaminants during your firm’s manufacturing processes. Your firm did not identify the risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants and the potential impact to patient harm. Your firm’s risk management files were not updated after identifying this new risk, including identifying the severity of patient harm, as required by your procedure.\u003C\u002Fp>\u003Cp>Additionally, your firm did not reevaluate the probability of occurrence for potential contaminants. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Supplier error leading to particulate contamination resulting in transient inflammation defines a probability occurrence of Improbable. Your firm did not update the occurrence probability after identifying the new risk of potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants.\u003C\u002Fp>\u003Cp>According to your firm’s Senior Manager, New Product Initiatives and Sustaining Engineering, since your firm implemented the demineralized process in 2008, \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates may have been present in your DBM, potentially impacting over \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address risk management deficiencies identified in Observation 3. Although your firm acknowledges that risk assessment associated with CAPA 157738 and related PFMEAs and Hazard Analysis (HA-\u003Cstrong>(b)(4)\u003C\u002Fstrong>) required revision and initiated procedural changes, your response is still inadequate. Your firm’s actions included:\u003C\u002Fp>\u003Cul>\u003Cli>Updated PMFEAs (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Updated Hazard Analysis HA-\u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Conducted a retrospective Health Hazard Evaluation (HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong>)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong> concluded that no correction, removal, or recall recommended, as the risk level assessed as Low and Acceptable. Your firm acknowledges that \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination occurred from 2008-2024, with over \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices potentially affected, however no actual testing was performed to confirm the absence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in distributed product. The HHE is deficient in that:\u003C\u002Fp>\u003Cul>\u003Cli>Your firm reviewed \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints and deemed \u003Cstrong>(b)(4)\u003C\u002Fstrong> clinically relevant for your probability calculation. There was no clear indication on which were not deemed clinically relevant and why. Your firm concluded that \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints related to \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination without adequately documenting an investigation showing how they ruled out \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination as a contributing factor.\u003C\u002Fli>\u003Cli>Your firm’s Probability Assessment disregards potential inflammation or foreign body reaction due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles as typical post-surgical inflammation\u003C\u002Fli>\u003Cli>Severity Assessment deemed Moderate, which firm has defined in your firm’s procedure, Risk Management Rev. J1 Effective: 5\u002F27\u002F22 and identified in the Severity Ratings Table in HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong> as a minor intervention (i.e. Medical intervention that may result in procedural delay, requiring removal and re-insertion of device resulting in additional patient discomfort or increased anesthesia requirements; Minor, transient, or self-limiting injury not requiring medical intervention; Cancellation of an elective medical procedure \u002F surgery). While complaint data included in HHE includes revision surgery, hospitalization, IV antibiotics, osteolysis consistent with a higher severity rating as noted in your procedure.\u003C\u002Fli>\u003Cli>Biocompatibility has not been adequately evaluated. Your firm states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used in permanently implanted devices (stents, pledgets, endoprostheses), therefore, \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure is not expected to cause adverse effects. However, the cited devices use intact \u003Cstrong>(b)(4)\u003C\u002Fstrong> structures, not particulate contamination. Your firm provides no data demonstrating that they have:\u003Cbr>o Characterized potential particle generation during normal use and wear.\u003Cbr>o Conducted biocompatibility testing per ISO 10993 standards if particle release is expected.\u003Cbr>o Assessed the clinical significance of any particle elution through risk analysis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on October 6, 2025 through October 17, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose, or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “\u003Cstrong>CMS Case 723370\u003C\u002Fstrong>” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden&nbsp;&nbsp;\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPeter P. Nalbach\n\nRecipient Title\n\nVice President and General Manager of Spine Operations\n\nIsoTis OrthoBiologics, Inc.\n\n2 Goodyear, Ste A,\n\nIrvine, CA 92618\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #723370\nFebruary 24, 2026\nDear Mr. Nalbach:\nDuring an inspection of your firm located in Irvine, CA from October 6, 2025, through October 17, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures resorbable calcium salt bone void filler devices, branded under the Accell Family of products, to include the Accell Evo3c. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, your manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from your Director Quality Systems, dated November 7, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example:\nYour firm failed to adequately take action to correct the cause of nonconformities in order to prevent recurrence. Your firm's corrective and preventative action procedure, Corrective and Preventive Actions CP-1001 Rev. J Effective: 8\u002F22\u002F2022, requires your firm to perform an investigation, determine the need for containment, and assess the risk associated with the issue.\nYour firm opened CAPA 157738 on 7\u002F27\u002F23 to address potential (b)(4) particulate contamination occurring during the demineralization process of bone tissue, due to the propeller blade contacting the bottom of the demineralization vessel. The issue was discovered by a manufacturing engineer and documented in emails dating back to 06\u002F22\u002F2023.\nAs part of CAPA 157738, your firm conducted a risk assessment for the demineralization process. In your risk analysis document, PFMEA-011 Rev. 12, effective October 23, 2023, your firm identified (b)(4) as a risk for particulate contamination. This risk was assigned a severity rating of Moderate and a probability of Improbable, resulting in an overall Acceptable risk rating. Despite discovering that the propeller blade was potentially shedding (b)(4) particles during demineralization, your firm did not investigate whether this finding affected your risk probability rating. In CAPA 157738, your firm classified the risk as low without providing justification for this conclusion and determined that containment action was not required due to your determined low risk. Your firm's CAPA investigation and actions are inadequate because it did not assess the potential impact to finished devices, including distributed product.\nAdditionally, your firm’s Verification of Effectiveness included reviewing 18 work orders to confirm that visual inspection of the propeller was performed. The verification of effectiveness does not demonstrate that visual inspection of the propeller is sufficient to identify potential (b)(4) particulate in your firm's demineralized bone matrix (DBM). Your firm did not verify if the corrective actions performed were sufficient to correct the potential (b)(4) particulate contamination.\nYour firm closed CAPA 157738 on 12\u002F17\u002F2024 without evidence that (b)(4) particulate contamination was no longer occurring during your demineralization process.\nWe reviewed your firm’s response and conclude that it is not adequate. While your firm’s response acknowledges procedural deficiencies and proposes process improvements, the CAPA defers critical product risk elements to separate CAPAs without clear indication that all deficiencies identified in CAPA-157738 have been adequately addressed. For example, in HHE-(b)(4), your firm identified (b)(4) complaints determined to be relevant now that (b)(4) contamination has been identified as a potential contributing factor. However, none of the related CAPAs indicate whether an MDR assessment was performed for these complaints.\nAdditionally, it is not clear why the scope of the CAPA retrospective review is from 01\u002F01\u002F2022 to present.\n2. Failure to revalidate a validated process when changes or process deviations occurred, as required by 21 CFR 820.75(c). For example:\nYour firm’s procedure, Validation Program QA-035 Effective: 6\u002F11\u002F21, requires revalidation for previously validated process parameters, component changes, and major design changes; however, your firm did not revalidate your demineralization press when a major design change was made.\nYour firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding that during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating the potential shedding of (b)(4) particulates. Two corrective actions were implemented:\n(b)(4)\n(b)(4)\nYour firm updated TL-0091 for the Demineralization Press in design change order (DCO), DCO 6306 Released: 5\u002F24\u002F24, which changed the equipment design by (b)(4). Your firm determined that qualification or validation is not required, though the DCO describes the change category as Major. Your firm answered No to the question: Is there a change in the manufacturing equipment while maintaining the existing process? on your Form CPF-0302-001 Decision Tree, although your firm changed the equipment design by (b)(4). Your firm’s Director of Quality Systems and Assurance told the investigator that they considered the demineralization press to be a tool and not equipment.\nAdditionally, your firm determined that (b)(4) inspection was sufficient to identify potential (b)(4) contaminants and required training of your demineralization team to (b)(4) inspect the propellers, however your firm has not validated the (b)(4) inspection process for the propeller blades to demonstrate it is sufficient in identifying potential (b)(4) contaminants in your firm’s demineralized bone matrix (DBM). In an email from your firm’s manufacturing engineer, they note that (b)(4) particulates are (b)(4).\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address production and process related deficiencies identified in Observation 2. Actions include validating the (b)(4) inspection method with (b)(4) study, completing Installation Qualification for all (b)(4) demineralization assemblies, and establishing preventative maintenance and calibration programs. However, while your firm validated the inspection method and qualified equipment, there is no objective evidence that:\nAn evaluation of the existing process validation was conducted to determine if the changes to the demineralization assemblies could impact the applicability of the existing Operational and Performance Qualifications.\n(b)(4) particulate contamination is no longer occurring in production and that the (b)(4)\" clearance is sufficient to prevent all contact under all operating conditions\nTesting has been performed to confirm absence of (b)(4) particles in DBM\nFurthermore, the verification of effectiveness plan measures compliance to procedures and execution of preventative maintenance but does not include testing for (b)(4) particulates in finished product.\nAdditionally, it is not clear why the scope identified in CAPA-100520 for reviewing tooling changes is January 2022 to present, when the affected timeframe extends back to 2008.\n3. Failure to establish an adequate risk analysis, as required by 21 CFR 820.30(g). For example:\nYour firm’s procedure, CP-0305 Risk Management Rev. J1 Effective: 5\u002F27\u002F22, requires in Section 6.26.2 Perform Risk Reassessment (As Necessary), that if new or updated risk information is identified, it will be fed back into the risk management system and documented via update and approval of the appropriate risk management forms (such as the Hazard Analysis or FMEA).\nYour firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding, during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating potential shedding of (b)(4) particulates. The CAPA identified the risk in PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II as (b)(4) for Supplier error leading to particulate contamination resulting in transient inflammation, which defined a severity of Moderate and a probability occurrence of Improbable, and the Risk Acceptability as Acceptable.\nYour firm identified the propeller blade was potentially shedding (b)(4) particulates during the demineralization process; however, your firm did not update PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II to identify this new risk factor. (b)(4) only addresses potential contaminants from your supplier resulting in transient inflammation and does not address the risk of contaminants during your firm’s manufacturing processes. Your firm did not identify the risk of (b)(4) contaminants and the potential impact to patient harm. Your firm’s risk management files were not updated after identifying this new risk, including identifying the severity of patient harm, as required by your procedure.\nAdditionally, your firm did not reevaluate the probability of occurrence for potential contaminants. (b)(4) Supplier error leading to particulate contamination resulting in transient inflammation defines a probability occurrence of Improbable. Your firm did not update the occurrence probability after identifying the new risk of potential (b)(4) contaminants.\nAccording to your firm’s Senior Manager, New Product Initiatives and Sustaining Engineering, since your firm implemented the demineralized process in 2008, (b)(4) particulates may have been present in your DBM, potentially impacting over (b)(4) devices.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address risk management deficiencies identified in Observation 3. Although your firm acknowledges that risk assessment associated with CAPA 157738 and related PFMEAs and Hazard Analysis (HA-(b)(4)) required revision and initiated procedural changes, your response is still inadequate. Your firm’s actions included:\nUpdated PMFEAs ((b)(4)) to include (b)(4)\nUpdated Hazard Analysis HA-(b)(4) to (b)(4)\nConducted a retrospective Health Hazard Evaluation (HHE-(b)(4))\nHHE-(b)(4) concluded that no correction, removal, or recall recommended, as the risk level assessed as Low and Acceptable. Your firm acknowledges that (b)(4) contamination occurred from 2008-2024, with over (b)(4) devices potentially affected, however no actual testing was performed to confirm the absence of (b)(4) in distributed product. The HHE is deficient in that:\nYour firm reviewed (b)(4) complaints and deemed (b)(4) clinically relevant for your probability calculation. There was no clear indication on which were not deemed clinically relevant and why. Your firm concluded that (b)(4) complaints related to (b)(4) contamination without adequately documenting an investigation showing how they ruled out (b)(4) contamination as a contributing factor.\nYour firm’s Probability Assessment disregards potential inflammation or foreign body reaction due to (b)(4) particles as typical post-surgical inflammation\nSeverity Assessment deemed Moderate, which firm has defined in your firm’s procedure, Risk Management Rev. J1 Effective: 5\u002F27\u002F22 and identified in the Severity Ratings Table in HHE-(b)(4) as a minor intervention (i.e. Medical intervention that may result in procedural delay, requiring removal and re-insertion of device resulting in additional patient discomfort or increased anesthesia requirements; Minor, transient, or self-limiting injury not requiring medical intervention; Cancellation of an elective medical procedure \u002F surgery). While complaint data included in HHE includes revision surgery, hospitalization, IV antibiotics, osteolysis consistent with a higher severity rating as noted in your procedure.\nBiocompatibility has not been adequately evaluated. Your firm states that (b)(4) is used in permanently implanted devices (stents, pledgets, endoprostheses), therefore, (b)(4) exposure is not expected to cause adverse effects. However, the cited devices use intact (b)(4) structures, not particulate contamination. Your firm provides no data demonstrating that they have:\no Characterized potential particle generation during normal use and wear.\no Conducted biocompatibility testing per ISO 10993 standards if particle release is expected.\no Assessed the clinical significance of any particle elution through risk analysis.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on October 6, 2025 through October 17, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose, or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 723370” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","IsoTis OrthoBiologics, Inc.","isotis-orthobiologics-inc-723370-02242026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fisotis-orthobiologics-inc-723370-02242026","2026-10-26T08:09:01.474861+00:00","2026-03-24","723370","Medical Devices","Peter P. Nalbach","2026-08-19T04:50:13.031+00:00","VIA Electronic Mail","2026-02-24",{"id":77,"raw":78,"subject":84,"body_html":85,"body_text":86,"firm_name":87,"letter_id":88,"created_at":89,"fei_number":19,"letter_url":90,"updated_at":91,"action_type":22,"case_status":23,"posted_date":92,"marcs_cms_no":93,"product_type":49,"closeout_date":19,"issuing_office":82,"recipient_name":94,"body_fetched_at":95,"delivery_method":96,"recipient_title":19,"reference_number":97,"action_taken_date":98,"medical_device_id":19,"response_letter_date":19},696,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-15T04:00:00Z\">08\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fplatinum-biologics-llc-705090-08152025\">Platinum Biologics LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-705090\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Beeben Russell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman of the Board \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Platinum Biologics LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1510 E Colonial Drive, Suite 103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orlando\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@platinumbiologics.com\"> support@platinumbiologics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 15, 2025\u003C\u002Fp>\u003Cp>CBER 25-705090\u003C\u002Fp>\u003Cp>Dear Mr. Russell:&nbsp;\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website at www.platinumbiologics.com\u002F (last visited August 2025), through which your company sells two umbilical cord derived products, Nano PRP Jelly and Nano Flex, and two exosome products, NanoEx and Nano Xsomes, for allogeneic use (collectively, “your products”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under sections 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).&nbsp;\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website, www.platinumbiologics.com\u002F (last visited August 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your products are intended for use in the treatment of autoimmune disease, pain, depression, and the repair of age-related and trauma-related defects in connective tissue.&nbsp;\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).&nbsp;\u003C\u002Fp>\u003Cp>Your Nano PRP Jelly and Nano Flex products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your establishment does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your Nano PRP Jelly and Nano Flex products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form and flowable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.&nbsp;\u003C\u002Fp>\u003Cp>In addition, your Nano PRP Jelly and Nano Flex products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for healing, the repair of age-related and trauma related defects in connective tissue, shoulder injuries, and heart failure, which are not basic functions of umbilical cord tissue in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.&nbsp;\u003C\u002Fp>\u003Cp>Your exosome products, NanoEx and Nano Xsomes are also drugs, as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as discussed above, and are subject to premarket review and approval requirements. We direct your attention to FDA’s public safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.&nbsp;\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.&nbsp;\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc:&nbsp;\u003C\u002Fp>\u003Cp>Stephen Mesa\u003Cbr>Co-Founder\u003Cbr>Platinum Biologics, LLC\u003Cbr>1510 E. Colonial Drive, Suite 100\u003Cbr>Orlando, FL 32803\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that you also market an umbilical cord derived product, Nano Flow, on your Facebook page, www.facebook.com\u002Fbeeben.russell\u002F. Umbilical cord derived products used to treat diseases and conditions in humans generally are regulated as drugs and biological products under the FD&amp;C Act and the PHS Act, and as such, would be subject to all applicable requirements, including premarket review and current good manufacturing practice requirements. 21 CFR 1271.20.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your Nano PRP Jelly and Nano Flex products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 25-705090\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nBeeben Russell\n\nRecipient Title\n\nChairman of the Board\n\nPlatinum Biologics LLC\n\n1510 E Colonial Drive, Suite 103\n\nOrlando, FL 32803\n\nUnited States\n\nsupport@platinumbiologics.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nAugust 15, 2025\nCBER 25-705090\nDear Mr. Russell:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website at www.platinumbiologics.com\u002F (last visited August 2025), through which your company sells two umbilical cord derived products, Nano PRP Jelly and Nano Flex, and two exosome products, NanoEx and Nano Xsomes, for allogeneic use (collectively, “your products”).1 This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under sections 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website, www.platinumbiologics.com\u002F (last visited August 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your products are intended for use in the treatment of autoimmune disease, pain, depression, and the repair of age-related and trauma-related defects in connective tissue.\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour Nano PRP Jelly and Nano Flex products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your establishment does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nSpecifically, your Nano PRP Jelly and Nano Flex products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form and flowable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your Nano PRP Jelly and Nano Flex products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for healing, the repair of age-related and trauma related defects in connective tissue, shoulder injuries, and heart failure, which are not basic functions of umbilical cord tissue in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nYour exosome products, NanoEx and Nano Xsomes are also drugs, as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as discussed above, and are subject to premarket review and approval requirements. We direct your attention to FDA’s public safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc:\nStephen Mesa\nCo-Founder\nPlatinum Biologics, LLC\n1510 E. Colonial Drive, Suite 100\nOrlando, FL 32803\n__________________\n1 We note that you also market an umbilical cord derived product, Nano Flow, on your Facebook page, www.facebook.com\u002Fbeeben.russell\u002F. Umbilical cord derived products used to treat diseases and conditions in humans generally are regulated as drugs and biological products under the FD&C Act and the PHS Act, and as such, would be subject to all applicable requirements, including premarket review and current good manufacturing practice requirements. 21 CFR 1271.20.\n2 Because your Nano PRP Jelly and Nano Flex products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Platinum Biologics LLC","platinum-biologics-llc-705090-08152025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fplatinum-biologics-llc-705090-08152025","2026-10-26T08:09:42.645343+00:00","2025-08-26","705090","Beeben Russell","2026-08-19T16:29:05.979+00:00","Via UPS and EMAIL","CBER 25-705090","2025-08-15",{"id":100,"raw":101,"subject":106,"body_html":107,"body_text":108,"firm_name":109,"letter_id":110,"created_at":44,"fei_number":19,"letter_url":111,"updated_at":112,"action_type":22,"case_status":23,"posted_date":113,"marcs_cms_no":114,"product_type":115,"closeout_date":19,"issuing_office":82,"recipient_name":116,"body_fetched_at":117,"delivery_method":118,"recipient_title":19,"reference_number":119,"action_taken_date":120,"medical_device_id":19,"response_letter_date":19},1165,[102,103,104,82,105,13,13,13],"\u003Ctime datetime=\"2024-11-19T14:20:00Z\">11\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-01T04:00:00Z\">11\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffrontier-biologics-llc-686059-11012024\">Frontier Biologics, LLC\u003C\u002Fa>","Unapproved New Drug\u002FUnlicensed Biological Product Violations\u003Cbr \u002F>\r\n","Unapproved New Drug\u002FUnlicensed Biological Product Violations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-686059\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chad W. Justice\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FFounder \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Frontier Biologics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>720 Jewell Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waco\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76712\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Chad@FrontierBiologics.com\"> Chad@FrontierBiologics.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 1, 2024&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25-686059\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Justice:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address between February 27, 2024, and March 8, 2024. During the inspection, FDA documented that your company manufactures a human amniotic fluid derived product, Purified Fluid Allograft, as well as a human amniotic membrane derived product, Allograft Matrix, for allogeneic use (collectively, “your products”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under sections 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your products are intended for wound healing, to lower inflammation, or for orthopedic use, as evidenced by the following statements in materials collected during the inspection:\u003C\u002Fp>\u003Cul>\u003Cli>“Purified Amniotic Fluid Allograft…can be applied directly at the site of injury, pain, or inflammation with a simple injection…Once introduced, it causes a systemic healing cascade in the body, targeting the site of injection.”\u003C\u002Fli>\u003Cli>“[Purified Amniotic Fluid Allograft] Applications [include]:\u003Cbr>o Muscle Tears\u003Cbr>o Soft Tissue Injuries\u003Cbr>o Wounds, Acute and Chronic\u003Cbr>o Osteoarthritis\u003Cbr>o Joint Injuries \u002F Pain”\u003C\u002Fli>\u003Cli>“Allograft [Matrix]…Benefits:\u003Cbr>o Catalyzes natural healing process to support proper remodeling\u003Cbr>o Provides specific signaling which lowers the body’s inflammatory response\u003Cbr>o Mitigates formation of scar tissue”\u003C\u002Fli>\u003Cli>“Allograft [Matrix]…Use:\u003Cbr>o … assists in wound healing, both chronic and acute.\u003Cbr>o … is used to enhance healing after a primary surgical repair.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your Allograft Matrix product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your company does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your Allograft Matrix product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a barrier for amniotic membrane). Rather, your product is intended for use in catalyzing wound healing and reducing inflammation, which is not a basic function of amniotic membrane in the donor.\u003C\u002Fp>\u003Cp>Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483).\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b).\u003C\u002Fstrong> For example, you failed to adequately validate (i.e., by performing media fill simulations) the aseptic process used to manufacture your Purified Fluid Allograft product. Your product purports to be sterile and is expected to be sterile.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess, as required by 21 CFR 211.100(a).\u003C\u002Fstrong> Specifically,\u003C\u002Fp>\u003Cp>a. The manufacturing process for your Purified Fluid Allograft product has not been adequately validated with respect to identity, strength, quality, and purity. During the inspection, you provided a validation study for your amniotic fluid product, which only tested for sterility. However, this is not sufficient to assure the identity, strength, quality, and purity of your product.\u003C\u002Fp>\u003Cp>b. The manufacturing process for your Allograft Matrix product has not been validated with respect to identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Aseptic processing areas are deficient regarding the system for environmental monitoring to prevent contamination, as required by 21 CFR 211.42(c)(10)(iv).\u003C\u002Fstrong> For example, you have not performed non-viable particulate monitoring, personnel monitoring, active or passive viable air sampling, or sampling of critical surfaces for microorganisms in the aseptic processing area in association with each production batch.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v).\u003C\u002Fstrong> For example, you have not validated your process for cleaning and disinfecting the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanrooms where your products are manufactured.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Written records are not always made of investigations into unexplained discrepancies or the failure of a batch or any of its components to meet specifications whether or not the batch has already been distributed , as required by 21 CFR 211.192.\u003C\u002Fstrong> For example, from March 2023 and June 2023, your firm had two sterility failures during finished product testing of your Purified Fluid Allograft product. Although you identified the contaminating organisms, you failed to conduct an investigation to determine the root cause of the failures.\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates, as required by 21 CFR 211.166(a).\u003C\u002Fstrong> Specifically, you assigned a \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date to your products without supporting data.\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your response, dated March 28, 2024, to FDA’s Form FDA-483 in detail. Your response is inadequate because it did not provide sufficient detail for FDA to fully assess the adequacy of your corrective actions. It lacks documentation to demonstrate that you have corrected your violations and fails to include a timeline for completion of all necessary corrective actions. For example, in your response, you note that going forward, any vials still in house from previously opened lots will be discarded. However, your response does not address the rubber stoppers and metal caps, which are used as packaging for your finished amniotic fluid products, that are \u003Cstrong>(b)(4)\u003C\u002Fstrong> using a sterilization process that has not been validated. Please be advised that in accordance with 21 CFR 211.113(b), you are required to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of sterilization processes.\u003C\u002Fp>\u003Cp>Your response also does not address your specific plans for disposition of the inventory of Purified Fluid Allograft or Allograft Matrix at your facility that were manufactured under the conditions described in this letter. Further, your response does not address products that have been distributed and remain in the marketplace.\u003C\u002Fp>\u003Cp>We acknowledge your commitment to voluntarily suspend production activities until you have made corrections to the observations listed on the Form FDA-483. However, your response does not adequately address your failure to have an IND in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect for that product, as specified by FDA regulations, that covers such clinical use. 21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> At the time of the inspection, FDA collected evidence that your human amniotic fluid derived product is also referred to as “Evexcell™ Purified Nanoparticle Fluid,” “Purified Amniotic Fluid Allograft,” “Purified Amniotic Fluid,” “Trophic Fluid Allograft,” “Trophic Factor Amniotic Fluid,” “Trophic Factor Purified Fluid Allograft,” and “Cryovial”. FDA also collected evidence that your human amniotic membrane derived product is also referred to as “Allograft Patch,” “Dual Layer Allograft Matrix,” “Dual Layer Allograft Patch,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “Patch Matrix,” “Matrix,” “Amniotic Membrane,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Allograft Patch,” and “Membrane.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that your amniotic fluid product, Purified Fluid Allograft, is not an HCT\u002FP because amniotic fluid is a secreted bodily fluid and the definition of HCT\u002FPs in 21 CFR 1271.3(d)(3) excludes secreted or extracted human products.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nReference #:\n\nCBER 25-686059\n\nProduct:\n\nBiologics\nDrugs\n\nRecipient:\n\nRecipient Name\n\nChad W. Justice\n\nRecipient Title\n\nPresident\u002FFounder\n\nFrontier Biologics, LLC\n\n720 Jewell Drive\n\nWaco, TX 76712\n\nUnited States\n\nChad@FrontierBiologics.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nNovember 1, 2024\nCBER 25-686059\nDear Mr. Justice:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address between February 27, 2024, and March 8, 2024. During the inspection, FDA documented that your company manufactures a human amniotic fluid derived product, Purified Fluid Allograft, as well as a human amniotic membrane derived product, Allograft Matrix, for allogeneic use (collectively, “your products”).1\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under sections 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your products are intended for wound healing, to lower inflammation, or for orthopedic use, as evidenced by the following statements in materials collected during the inspection:\n“Purified Amniotic Fluid Allograft…can be applied directly at the site of injury, pain, or inflammation with a simple injection…Once introduced, it causes a systemic healing cascade in the body, targeting the site of injection.”\n“[Purified Amniotic Fluid Allograft] Applications [include]:\no Muscle Tears\no Soft Tissue Injuries\no Wounds, Acute and Chronic\no Osteoarthritis\no Joint Injuries \u002F Pain”\n“Allograft [Matrix]…Benefits:\no Catalyzes natural healing process to support proper remodeling\no Provides specific signaling which lowers the body’s inflammatory response\no Mitigates formation of scar tissue”\n“Allograft [Matrix]…Use:\no … assists in wound healing, both chronic and acute.\no … is used to enhance healing after a primary surgical repair.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).2\nYour Allograft Matrix product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your company does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).\nFor example, your Allograft Matrix product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a barrier for amniotic membrane). Rather, your product is intended for use in catalyzing wound healing and reducing inflammation, which is not a basic function of amniotic membrane in the donor.\nTherefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.3 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483).\nThe CGMP violations applicable to your products include, but are not limited to, the following:\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b). For example, you failed to adequately validate (i.e., by performing media fill simulations) the aseptic process used to manufacture your Purified Fluid Allograft product. Your product purports to be sterile and is expected to be sterile.\n2. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess, as required by 21 CFR 211.100(a). Specifically,\na. The manufacturing process for your Purified Fluid Allograft product has not been adequately validated with respect to identity, strength, quality, and purity. During the inspection, you provided a validation study for your amniotic fluid product, which only tested for sterility. However, this is not sufficient to assure the identity, strength, quality, and purity of your product.\nb. The manufacturing process for your Allograft Matrix product has not been validated with respect to identity, strength, quality, and purity.\n3. Aseptic processing areas are deficient regarding the system for environmental monitoring to prevent contamination, as required by 21 CFR 211.42(c)(10)(iv). For example, you have not performed non-viable particulate monitoring, personnel monitoring, active or passive viable air sampling, or sampling of critical surfaces for microorganisms in the aseptic processing area in association with each production batch.\n4. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v). For example, you have not validated your process for cleaning and disinfecting the ISO (b)(4) cleanrooms where your products are manufactured.\n5. Written records are not always made of investigations into unexplained discrepancies or the failure of a batch or any of its components to meet specifications whether or not the batch has already been distributed , as required by 21 CFR 211.192. For example, from March 2023 and June 2023, your firm had two sterility failures during finished product testing of your Purified Fluid Allograft product. Although you identified the contaminating organisms, you failed to conduct an investigation to determine the root cause of the failures.\n6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates, as required by 21 CFR 211.166(a). Specifically, you assigned a (b)(4) expiration date to your products without supporting data.\nResponse to the Form FDA-483\nWe have reviewed your response, dated March 28, 2024, to FDA’s Form FDA-483 in detail. Your response is inadequate because it did not provide sufficient detail for FDA to fully assess the adequacy of your corrective actions. It lacks documentation to demonstrate that you have corrected your violations and fails to include a timeline for completion of all necessary corrective actions. For example, in your response, you note that going forward, any vials still in house from previously opened lots will be discarded. However, your response does not address the rubber stoppers and metal caps, which are used as packaging for your finished amniotic fluid products, that are (b)(4) using a sterilization process that has not been validated. Please be advised that in accordance with 21 CFR 211.113(b), you are required to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of sterilization processes.\nYour response also does not address your specific plans for disposition of the inventory of Purified Fluid Allograft or Allograft Matrix at your facility that were manufactured under the conditions described in this letter. Further, your response does not address products that have been distributed and remain in the marketplace.\nWe acknowledge your commitment to voluntarily suspend production activities until you have made corrections to the observations listed on the Form FDA-483. However, your response does not adequately address your failure to have an IND in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect for that product, as specified by FDA regulations, that covers such clinical use. 21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n_________________________\n1 At the time of the inspection, FDA collected evidence that your human amniotic fluid derived product is also referred to as “Evexcell™ Purified Nanoparticle Fluid,” “Purified Amniotic Fluid Allograft,” “Purified Amniotic Fluid,” “Trophic Fluid Allograft,” “Trophic Factor Amniotic Fluid,” “Trophic Factor Purified Fluid Allograft,” and “Cryovial”. FDA also collected evidence that your human amniotic membrane derived product is also referred to as “Allograft Patch,” “Dual Layer Allograft Matrix,” “Dual Layer Allograft Patch,” “(b)(4),” “Patch Matrix,” “Matrix,” “Amniotic Membrane,” “(b)(4) Allograft Patch,” and “Membrane.”\n2 We note that your amniotic fluid product, Purified Fluid Allograft, is not an HCT\u002FP because amniotic fluid is a secreted bodily fluid and the definition of HCT\u002FPs in 21 CFR 1271.3(d)(3) excludes secreted or extracted human products.\n3 Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Frontier Biologics, LLC","frontier-biologics-llc-686059-11012024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffrontier-biologics-llc-686059-11012024","2026-10-26T08:08:43.737712+00:00","2024-11-19","686059","BiologicsDrugs","Chad W. Justice","2026-08-19T18:14:09.235+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","CBER 25-686059","2024-11-01",{"id":122,"raw":123,"subject":84,"body_html":129,"body_text":130,"firm_name":131,"letter_id":132,"created_at":133,"fei_number":19,"letter_url":134,"updated_at":135,"action_type":22,"case_status":136,"posted_date":137,"marcs_cms_no":138,"product_type":49,"closeout_date":139,"issuing_office":140,"recipient_name":141,"body_fetched_at":142,"delivery_method":143,"recipient_title":19,"reference_number":144,"action_taken_date":145,"medical_device_id":19,"response_letter_date":19},1821,[124,125,126,127,83,13,128,13],"\u003Ctime datetime=\"2023-09-29T21:00:00Z\">09\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-18T04:00:00Z\">09\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsignature-biologics-llc-631039-09182023\">Signature Biologics, LLC\u003C\u002Fa>"," Division of Biological Products Operations II","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsignature-biologics-llc-631039-02212025\">\u003Ctime datetime=\"2025-03-06T05:00:00Z\">03\u002F06\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 23-631039\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Neil H. Riordan, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Signature Biologics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4040 W. Royal Lane, Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irving\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75063-2844\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:neil@aidanresearch.com\"> neil@aidanresearch.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Biological Products Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> #OBPO 23-631039\u003C\u002Fp>\n\n\u003Cp>September 18, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Riordan:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Signature Biologics, LLC, located at 4040 W. Royal Lane, Suite 100, Irving, TX 75063, conducted between December 1, 2021, and December 16, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of Signature Cord™, a product derived from human umbilical cord (“your product”) for allogeneic use.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You have distributed Signature Cord™ directly to health care professionals and medical facilities for use in patients. Your product is intended for injection and purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during and\u002For after the inspection reflect that your product is intended to treat diseases or conditions. Additionally, information collected indicates that your product fits within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your product is a drug as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological product as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of the materials described above, Signature Biologics, LLC does not qualify for any exception in 21 CFR 1271.15, and Signature Cord™ fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, Signature Cord™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product. Based on this information, your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your product. FDA identified additional significant deviations upon further review of the information collected during the inspection, as discussed below. These CGMP deviations, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of your product manufactured and distributed between November 2018 and December 2021, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile [21 CFR 211.113(b)].\u003C\u002Fstrong> Your firm failed to adequately validate the aseptic processes used to manufacture your Signature Cord™ product in that the media fill batches used for your validation studies did not represent the maximum commercial batch size. For example, your validation studies entitled “Aseptic Processing Validation Report—Signature Cord” utilized a maximum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials per batch. However, from November 2018 through February 2020, your firm manufactured \u003Cstrong>(b)(4)\u003C\u002Fstrong> commercial batches of Signature Cord™ with \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> Your firm has not established an adequate system for environmental monitoring in the aseptic processing areas where your products are manufactured. For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not performed microbiological monitoring of viable air in the ISO 7 supporting cleanrooms in association with each production run.\u003C\u002Fp>\n\n\u003Cp>b. Your environmental monitoring procedure describes the following as acceptable results for microbiological monitoring: \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs) for surfaces within the ISO 7 supporting cleanrooms, \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs for settling plate samples within the ISO 7 supporting cleanrooms, \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs for personnel glove samples within the ISO 7 supporting cleanrooms, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs for personnel garment samples within the ISO 7 supporting cleanrooms. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that the drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. \u003C\u002Fstrong>For example, at the time of the inspection, your finished product testing was limited to sterility testing as a measurement of product attributes.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Each of batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements [21 CFR 211.167(a)].\u003C\u002Fstrong> For example, your firm failed to perform endotoxin testing as a release criterion on \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of Signature Cord™ product manufactured and distributed by your firm since November 2018. By the nature of the route of administration, your product is purported to be pyrogen-free and is expected to be pyrogen-free.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example, the manufacturing process for your product has not been validated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example, at the time of the inspection, you had not validated your process for cleaning and disinfecting the Biological Safety Cabinets (BSCs) and supporting cleanrooms where your product was manufactured.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assigned a two-year expiration date to your product without supporting data.\u003C\u002Fp>\n\n\u003Cp>FDA received your written responses dated January 10, 2022, March 1, 2022, April 1, 2022, May 24, 2022, June 30, 2022, August 31, 2022, and November 2, 2022, to the inspectional observations on the Form FDA-483. The corrective actions described in your responses are not adequate to address the above-referenced deficiencies. We note that certain corrective actions cannot be evaluated because they lack supporting documentation. In addition, your responses do not address your specific plans for disposition of the inventory of Signature Cord™ at your facility. Additionally, for your previously distributed product, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed product that carries a two-year shelf life and was manufactured under the above-described conditions.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to voluntarily suspend the manufacture and distribution of Signature Cord™. However, your responses do not adequately address your failure to have an IND in effect to study your product addressed in this letter or your lack of an approved BLA to lawfully market your product. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with your firm at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response to this letter should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Products Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 271-1242 x 104 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCc: Chloe R. Bailey, President and Chief Operating Officer\u003Cbr>\nSignature Biologics, LLC\u003Cbr>\n4040 W. Royal Lane, Suite 100\u003Cbr>\nIrving, TX 75063-2844\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> During the December 2021 inspection, FDA also collected evidence that you have manufactured and marketed Signature Matrix\u003Csup>TM\u003C\u002Fsup> and Signature MatrixHX\u003Csup>TM\u003C\u002Fsup>, which are amniotic membrane derived products for allogeneic use. Your firm has represented that it ceased manufacturing these products in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that it discontinued their manufacture and distribution as of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is therefore FDA’s understanding that any previously manufactured Signature Matrix\u003Csup>TM\u003C\u002Fsup> and Signature MatrixHX\u003Csup>TM\u003C\u002Fsup> products are no longer within expiry. Based on information and records gathered prior to, during and\u002For after the inspection, Signature Matrix\u003Csup>TM\u003C\u002Fsup> and Signature MatrixHX\u003Csup>TM\u003C\u002Fsup> are intended to treat diseases or conditions in humans and are more than minimally manipulated. We note that these amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the “minimal manipulation” criterion at 21 CFR 1271.10(a)(1), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We also note that based on the information and records gathered prior to, during and\u002For after the inspection, Signature Cord\u003Csup>TM\u003C\u002Fsup> appears to be intended to treat orthopedic diseases and conditions, for example. Such uses are not considered homologous use of umbilical cord. Signature CordTM must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nOBPO 23-631039\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nNeil H. Riordan, Ph.D.\n\nRecipient Title\n\nChief Executive Officer\n\nSignature Biologics, LLC\n\n4040 W. Royal Lane, Suite 100\n\nIrving, TX 75063-2844\n\nUnited States\n\nneil@aidanresearch.com\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nWarning Letter #OBPO 23-631039\n\nSeptember 18, 2023\n\nDear Dr. Riordan:\n\nDuring an inspection of your firm, Signature Biologics, LLC, located at 4040 W. Royal Lane, Suite 100, Irving, TX 75063, conducted between December 1, 2021, and December 16, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of Signature Cord™, a product derived from human umbilical cord (“your product”) for allogeneic use.1 You have distributed Signature Cord™ directly to health care professionals and medical facilities for use in patients. Your product is intended for injection and purported to be sterile.\n\nInformation and records gathered prior to, during and\u002For after the inspection reflect that your product is intended to treat diseases or conditions. Additionally, information collected indicates that your product fits within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your product is a drug as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological product as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\n\nYour product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of the materials described above, Signature Biologics, LLC does not qualify for any exception in 21 CFR 1271.15, and Signature Cord™ fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, Signature Cord™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement.2\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product. Based on this information, your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act [21 U.S.C. 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\n\nAt the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your product. FDA identified additional significant deviations upon further review of the information collected during the inspection, as discussed below. These CGMP deviations, involving over (b)(4) vials of your product manufactured and distributed between November 2018 and December 2021, include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile [21 CFR 211.113(b)]. Your firm failed to adequately validate the aseptic processes used to manufacture your Signature Cord™ product in that the media fill batches used for your validation studies did not represent the maximum commercial batch size. For example, your validation studies entitled “Aseptic Processing Validation Report—Signature Cord” utilized a maximum of (b)(4) vials per batch. However, from November 2018 through February 2020, your firm manufactured (b)(4) commercial batches of Signature Cord™ with (b)(4) vials.\n\n2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area [21 CFR 211.42(c)(10)(iv)]. Your firm has not established an adequate system for environmental monitoring in the aseptic processing areas where your products are manufactured. For example:\n\na. You have not performed microbiological monitoring of viable air in the ISO 7 supporting cleanrooms in association with each production run.\n\nb. Your environmental monitoring procedure describes the following as acceptable results for microbiological monitoring: (b)(4) colony forming units (CFUs) for surfaces within the ISO 7 supporting cleanrooms, (b)(4) CFUs for settling plate samples within the ISO 7 supporting cleanrooms, (b)(4) CFUs for personnel glove samples within the ISO 7 supporting cleanrooms, and (b)(4) CFUs for personnel garment samples within the ISO 7 supporting cleanrooms. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern.\n\n3. Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that the drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, at the time of the inspection, your finished product testing was limited to sterility testing as a measurement of product attributes.\n\n4. Each of batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements [21 CFR 211.167(a)]. For example, your firm failed to perform endotoxin testing as a release criterion on (b)(4) units of Signature Cord™ product manufactured and distributed by your firm since November 2018. By the nature of the route of administration, your product is purported to be pyrogen-free and is expected to be pyrogen-free.\n\n5. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, the manufacturing process for your product has not been validated.\n\n6. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example, at the time of the inspection, you had not validated your process for cleaning and disinfecting the Biological Safety Cabinets (BSCs) and supporting cleanrooms where your product was manufactured.\n\n7. Failure to establish a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assigned a two-year expiration date to your product without supporting data.\n\nFDA received your written responses dated January 10, 2022, March 1, 2022, April 1, 2022, May 24, 2022, June 30, 2022, August 31, 2022, and November 2, 2022, to the inspectional observations on the Form FDA-483. The corrective actions described in your responses are not adequate to address the above-referenced deficiencies. We note that certain corrective actions cannot be evaluated because they lack supporting documentation. In addition, your responses do not address your specific plans for disposition of the inventory of Signature Cord™ at your facility. Additionally, for your previously distributed product, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed product that carries a two-year shelf life and was manufactured under the above-described conditions.\n\nWe acknowledge your commitment to voluntarily suspend the manufacture and distribution of Signature Cord™. However, your responses do not adequately address your failure to have an IND in effect to study your product addressed in this letter or your lack of an approved BLA to lawfully market your product. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with your firm at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response to this letter should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Products Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 271-1242 x 104 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\nCc: Chloe R. Bailey, President and Chief Operating Officer\n\nSignature Biologics, LLC\n\n4040 W. Royal Lane, Suite 100\n\nIrving, TX 75063-2844\n\n_______________________\n\n1 During the December 2021 inspection, FDA also collected evidence that you have manufactured and marketed Signature MatrixTM and Signature MatrixHXTM, which are amniotic membrane derived products for allogeneic use. Your firm has represented that it ceased manufacturing these products in (b)(4) and that it discontinued their manufacture and distribution as of (b)(4). It is therefore FDA’s understanding that any previously manufactured Signature MatrixTM and Signature MatrixHXTM products are no longer within expiry. Based on information and records gathered prior to, during and\u002For after the inspection, Signature MatrixTM and Signature MatrixHXTM are intended to treat diseases or conditions in humans and are more than minimally manipulated. We note that these amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the “minimal manipulation” criterion at 21 CFR 1271.10(a)(1), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\n\n2 We also note that based on the information and records gathered prior to, during and\u002For after the inspection, Signature CordTM appears to be intended to treat orthopedic diseases and conditions, for example. Such uses are not considered homologous use of umbilical cord. Signature CordTM must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271.","Signature Biologics, LLC","signature-biologics-llc-631039-09182023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsignature-biologics-llc-631039-09182023","2026-10-26T08:09:57.530976+00:00","Closed Out","2023-09-29","631039","2025-03-06","Division of Biological Products Operations II","Neil H. Riordan, Ph.D.","2026-08-20T00:38:15.637+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","OBPO 23-631039","2023-09-18",{"id":147,"raw":148,"subject":153,"body_html":154,"body_text":155,"firm_name":156,"letter_id":157,"created_at":158,"fei_number":19,"letter_url":159,"updated_at":160,"action_type":22,"case_status":23,"posted_date":161,"marcs_cms_no":162,"product_type":26,"closeout_date":19,"issuing_office":152,"recipient_name":163,"body_fetched_at":164,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":165,"medical_device_id":19,"response_letter_date":19},3229,[149,150,151,152,153,13,13,13],"\u003Ctime datetime=\"2021-08-04T14:00:00Z\">08\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-03T04:00:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fblue-willow-biologics-613948-08032021\">Blue Willow Biologics\u003C\u002Fa>","Center for Drug Evaluation and Research","Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chad Costley, MD\u002FMBA\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Blue Willow Biologics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2311 Green Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ann Arbor\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nanobio@bluewillow.com\"> nanobio@bluewillow.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: August 3, 2021\u003Cbr>\n\u003Cbr>\nRE: Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) had reviewed your websites at the Internet addresses https:\u002F\u002Fnanobioprotect.com and https:\u002F\u002Fbluewillow.com on March 24, 2021. The FDA observed that your websites offered a non-alcohol-based consumer antiseptic nasal product\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> for sale in the United States and that this product was intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and other conditions in people. FDA also observed that your product is for sale in the United States on other websites, including at https:\u002F\u002Fwww.cvs.com\u002Fshop\u002Fnanobio-protect-nasal-antiseptic-prodid-160333. Based on our review, this product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under sections 502(a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee). Introduction or delivery for introduction of such a product into interstate commerce violated sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. 331(a) and (d). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sold an unapproved and unauthorized product that was intended to mitigate, prevent, treat, diagnose, or cure COVID-19 and other conditions in people.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your product label that establish the intended use of your product (as defined in 21 CFR 201.128) and examples of the claims on your website that established the intended use of your product and misleadingly represented it as safe and\u002For effective for the treatment or prevention of COVID-19 and other serious infections include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>NanoBioProtect.com and Bluewillow.com websites and NanoBio Protect Nasal Antiseptic label:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>NanoBio® Protect Over-The-Counter Nasal Antiseptic Kills COVID-19 Virus in Lab Tests.” [from your website https:\u002F\u002Fbluewillow.com\u002F%ef%bb%bf%ef%bb%bfnanobio-protect-over-the-counter-nasal-antiseptic-kills-covid-19-virus-in-lab-tests\u002F]\u003C\u002Fli>\n\t\u003Cli>“Recent studies conducted by Public Health England also demonstrate NanoBio® Protect’s ability to kill COVID-19 virus in laboratory test.” [from your website https:\u002F\u002Fbluewillow.com\u002Fnanobio-protect\u002F]\u003C\u002Fli>\n\t\u003Cli>“NanoBio Protect . . . Protects for up to 8 hours . . . Kills 99.99% of germs on contact . . . Reduces the risk of respiratory infection ….” [from your website https:\u002F\u002Fnanobioprotect.com\u002F]\u003C\u002Fli>\n\t\u003Cli>“KILLS GERMS THAT ENTER THE NOSE . . . PROTECTS FOR 8 HOURS . . .NEXT-LEVEL PROTECTION AGAINST INFECTION” [from your product label]\u003C\u002Fli>\n\t\u003Cli>“Get protection from infection that lasts all day.” [from your website https:\u002F\u002Fnanobioprotect.com\u002F]\u003C\u002Fli>\n\t\u003Cli>“NanoBio Protect offers next-level protection to help keep you and your family healthy. It is the only alcohol-free nasal antiseptic proven to kill 99.99% of infection-causing germs when applied to the skin in and around the nose. . . NanoBio Protect uses patented, natural-oil nanodroplets that deliver the antiseptic directly to the surface of germs, killing them on contact. Uniquely, the nanodroplets remain active on the skin after application for up to 8 hours (in lab testing), providing lasting protection against the germs that cause infection.” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\u003C\u002Fli>\n\t\u003Cli>“NanoBio Protect adds BZK antiseptic to the surface of nanodroplets. This technology offers four distinct advantages over conventional BZK antiseptics:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The Nanodroplets optimize the ability of the antiseptic to kill germs. The droplets sit on skin after application, enabling protection for up to 8 hours (in lab testing) . . .” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Is NanoBio Protect US FDA regulated? Yes. NanoBio® Protect nasal antiseptic adheres to the OTC monograph system for topical skin antiseptics. In testing by independent FDA registered laboratories, NanoBio® Protect was shown to kill 99.99% of a broad spectrum of pathogenic organisms. To learn more, visit https:\u002F\u002Fbluewillow.com\u002Fnanobio-protect\u002F.” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We note that, as of the date of this letter, some of the claims cited above appear to have been removed. Due to the serious public health concerns related to the marketing and sale of unapproved drugs for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, it is essential that these violations do not recur.\u003C\u002Fp>\n\n\u003Cp>Based on the above claims, your topical antiseptic product is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1)(B), because it is intended for the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, your product is intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>This consumer topical antiseptic is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your NanoBio Protect Nasal Antiseptic Solution product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, your consumer topical antiseptic product does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>Specifically, your labeling claims suggesting and depicting that your topical antiseptic product is effective in preventing infection or disease go beyond merely describing the general intended use of consumer antiseptics as set forth in the 1994 TFM.5 Your claims on the product label, suggesting your consumer antiseptic provides all day efficacy against infection, and your claims on your websites, which suggested all day protection against serious-disease related pathogens including the novel coronavirus that causes COVID-19, do not conform to the 1994 TFM or any of the amendments to the TFM discussed above. Time-specific extended efficacy claims, especially when related to serious-disease related pathogens, endanger the public health by creating a false sense of security for the general public that may result in infrequent hand washing or the substitution of these products for protective gloves and clothing, which are the principal methods for protecting against the spread of diseases caused by pathogenic microorganisms. As a result, this product may have given users the false impression that they need not rigorously adhere to interventions such as social distancing and exercising good hygienic practices that have been demonstrated to curb the spread of COVID-19. Users who did not follow these interventions were at increased risk for contracting COVID-19 and for spreading disease if they had been exposed to the virus, thereby prolonging the pandemic, and increasing its associated morbidity and mortality. In addition, according to the product labeling, NanoBio Protect Nasal Antiseptic Solution is intended to be applied inside and around the nostrils. Consumer antiseptic products intended for administration inside and around the nostrils are not permitted under the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>We are unaware of any adequate and well-controlled clinical studies in the published literature that support a determination that your consumer topical antiseptic product is GRASE for the above-described intended uses, including the time-specific extended efficacy claims. Accordingly, your consumer topical antiseptic product is a new drug under section 201(p) of the FD&amp;C Act. In addition, there are no FDA-approved applications in effect for your consumer topical antiseptic product and, accordingly, it is an unapproved new drug sold in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C §§ 355(a) and 331(d). We note that your consumer topical antiseptic product also does not conform to any temporary policy FDA has implemented for alcohol-based hand sanitizer products during the public health emergency.\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>This consumer topical antiseptic product was also misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because the labeling was false or misleading. Specifically, labeling for this product claimed that the product “adheres to the OTC monograph system for topical skin antiseptics.” As noted above, this product does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>This consumer topical antiseptic products is also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to prevent the recurrence of future violations. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act, with a notation that, as of the date of this letter, your firm’s listed products are no longer sold for the prevention, treatment, mitigation, diagnosis or cure of COVID-19. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products.Corrective actions taken to address the sale of your unapproved and unauthorized product for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have to be confirmed by the FDA, for the published list to be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot complete corrective action within 48 hours, state the reason for the delay and the time within which you will complete the corrections. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nDonald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your non-alcohol-based consumer antiseptic nasal product is NanoBio Protect Nasal Antiseptic Solution.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists. (originally issued on Jan. 31, 2020 and subsequently renewed) available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak. (Mar. 13, 2020), available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that potentially can cause disease and health care and consumer antiseptics that are indicated for use to decrease bacteria on the skin. 59 FR at 31443.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> The 2016 Consumer Antiseptic Rubs Proposed Rule covered consumer antiseptic products intended for use of without water. Under the 1994 TFM, as amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, only consumer topical antiseptic products intended for use on the hands without water are permitted. Products intended for other areas of the body such as the nose are not permitted.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem>. Because your consumer topical antiseptic product is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nChad Costley, MD\u002FMBA\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nBlue Willow Biologics\n\n2311 Green Road\n\nAnn Arbor, MI 48105\n\nUnited States\n\nnanobio@bluewillow.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWARNING LETTER\n\nDate: August 3, 2021\n\nRE: Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) had reviewed your websites at the Internet addresses https:\u002F\u002Fnanobioprotect.com and https:\u002F\u002Fbluewillow.com on March 24, 2021. The FDA observed that your websites offered a non-alcohol-based consumer antiseptic nasal product1 for sale in the United States and that this product was intended to mitigate, prevent, treat, diagnose, or cure COVID-192 and other conditions in people. FDA also observed that your product is for sale in the United States on other websites, including at https:\u002F\u002Fwww.cvs.com\u002Fshop\u002Fnanobio-protect-nasal-antiseptic-prodid-160333. Based on our review, this product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee). Introduction or delivery for introduction of such a product into interstate commerce violated sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a) and (d). These violations are described in more detail below.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sold an unapproved and unauthorized product that was intended to mitigate, prevent, treat, diagnose, or cure COVID-19 and other conditions in people.\n\nSome examples of the claims on your product label that establish the intended use of your product (as defined in 21 CFR 201.128) and examples of the claims on your website that established the intended use of your product and misleadingly represented it as safe and\u002For effective for the treatment or prevention of COVID-19 and other serious infections include, but may not be limited to, the following:\n\nNanoBioProtect.com and Bluewillow.com websites and NanoBio Protect Nasal Antiseptic label:\n\nNanoBio® Protect Over-The-Counter Nasal Antiseptic Kills COVID-19 Virus in Lab Tests.” [from your website https:\u002F\u002Fbluewillow.com\u002F%ef%bb%bf%ef%bb%bfnanobio-protect-over-the-counter-nasal-antiseptic-kills-covid-19-virus-in-lab-tests\u002F]\n\n“Recent studies conducted by Public Health England also demonstrate NanoBio® Protect’s ability to kill COVID-19 virus in laboratory test.” [from your website https:\u002F\u002Fbluewillow.com\u002Fnanobio-protect\u002F]\n\n“NanoBio Protect . . . Protects for up to 8 hours . . . Kills 99.99% of germs on contact . . . Reduces the risk of respiratory infection ….” [from your website https:\u002F\u002Fnanobioprotect.com\u002F]\n\n“KILLS GERMS THAT ENTER THE NOSE . . . PROTECTS FOR 8 HOURS . . .NEXT-LEVEL PROTECTION AGAINST INFECTION” [from your product label]\n\n“Get protection from infection that lasts all day.” [from your website https:\u002F\u002Fnanobioprotect.com\u002F]\n\n“NanoBio Protect offers next-level protection to help keep you and your family healthy. It is the only alcohol-free nasal antiseptic proven to kill 99.99% of infection-causing germs when applied to the skin in and around the nose. . . NanoBio Protect uses patented, natural-oil nanodroplets that deliver the antiseptic directly to the surface of germs, killing them on contact. Uniquely, the nanodroplets remain active on the skin after application for up to 8 hours (in lab testing), providing lasting protection against the germs that cause infection.” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\n\n“NanoBio Protect adds BZK antiseptic to the surface of nanodroplets. This technology offers four distinct advantages over conventional BZK antiseptics:\n\nThe Nanodroplets optimize the ability of the antiseptic to kill germs. The droplets sit on skin after application, enabling protection for up to 8 hours (in lab testing) . . .” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\n\n“Is NanoBio Protect US FDA regulated? Yes. NanoBio® Protect nasal antiseptic adheres to the OTC monograph system for topical skin antiseptics. In testing by independent FDA registered laboratories, NanoBio® Protect was shown to kill 99.99% of a broad spectrum of pathogenic organisms. To learn more, visit https:\u002F\u002Fbluewillow.com\u002Fnanobio-protect\u002F.” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\n\nWe note that, as of the date of this letter, some of the claims cited above appear to have been removed. Due to the serious public health concerns related to the marketing and sale of unapproved drugs for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, it is essential that these violations do not recur.\n\nBased on the above claims, your topical antiseptic product is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. § 321(g)(1)(B), because it is intended for the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. § 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, your product is intended for use as a consumer topical antiseptic.\n\nThis consumer topical antiseptic is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your NanoBio Protect Nasal Antiseptic Solution product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, your consumer topical antiseptic product does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nSpecifically, your labeling claims suggesting and depicting that your topical antiseptic product is effective in preventing infection or disease go beyond merely describing the general intended use of consumer antiseptics as set forth in the 1994 TFM.5 Your claims on the product label, suggesting your consumer antiseptic provides all day efficacy against infection, and your claims on your websites, which suggested all day protection against serious-disease related pathogens including the novel coronavirus that causes COVID-19, do not conform to the 1994 TFM or any of the amendments to the TFM discussed above. Time-specific extended efficacy claims, especially when related to serious-disease related pathogens, endanger the public health by creating a false sense of security for the general public that may result in infrequent hand washing or the substitution of these products for protective gloves and clothing, which are the principal methods for protecting against the spread of diseases caused by pathogenic microorganisms. As a result, this product may have given users the false impression that they need not rigorously adhere to interventions such as social distancing and exercising good hygienic practices that have been demonstrated to curb the spread of COVID-19. Users who did not follow these interventions were at increased risk for contracting COVID-19 and for spreading disease if they had been exposed to the virus, thereby prolonging the pandemic, and increasing its associated morbidity and mortality. In addition, according to the product labeling, NanoBio Protect Nasal Antiseptic Solution is intended to be applied inside and around the nostrils. Consumer antiseptic products intended for administration inside and around the nostrils are not permitted under the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule6.\n\nWe are unaware of any adequate and well-controlled clinical studies in the published literature that support a determination that your consumer topical antiseptic product is GRASE for the above-described intended uses, including the time-specific extended efficacy claims. Accordingly, your consumer topical antiseptic product is a new drug under section 201(p) of the FD&C Act. In addition, there are no FDA-approved applications in effect for your consumer topical antiseptic product and, accordingly, it is an unapproved new drug sold in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C §§ 355(a) and 331(d). We note that your consumer topical antiseptic product also does not conform to any temporary policy FDA has implemented for alcohol-based hand sanitizer products during the public health emergency.7\n\nThis consumer topical antiseptic product was also misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because the labeling was false or misleading. Specifically, labeling for this product claimed that the product “adheres to the OTC monograph system for topical skin antiseptics.” As noted above, this product does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nThis consumer topical antiseptic products is also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to prevent the recurrence of future violations. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure, and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act, with a notation that, as of the date of this letter, your firm’s listed products are no longer sold for the prevention, treatment, mitigation, diagnosis or cure of COVID-19. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products.Corrective actions taken to address the sale of your unapproved and unauthorized product for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have to be confirmed by the FDA, for the published list to be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot complete corrective action within 48 hours, state the reason for the delay and the time within which you will complete the corrections. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_______________________________\n\n1 Your non-alcohol-based consumer antiseptic nasal product is NanoBio Protect Nasal Antiseptic Solution.\n\n2 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists. (originally issued on Jan. 31, 2020 and subsequently renewed) available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak. (Mar. 13, 2020), available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\n\n5 The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that potentially can cause disease and health care and consumer antiseptics that are indicated for use to decrease bacteria on the skin. 59 FR at 31443.\n\n6 The 2016 Consumer Antiseptic Rubs Proposed Rule covered consumer antiseptic products intended for use of without water. Under the 1994 TFM, as amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, only consumer topical antiseptic products intended for use on the hands without water are permitted. Products intended for other areas of the body such as the nose are not permitted.\n\n7 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because your consumer topical antiseptic product is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","Blue Willow Biologics","blue-willow-biologics-613948-08032021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fblue-willow-biologics-613948-08032021","2026-10-26T08:08:06.851143+00:00","2021-08-04","613948","Chad Costley, MD\u002FMBA","2026-08-20T02:43:44.258+00:00","2021-08-03",{"id":167,"raw":168,"subject":84,"body_html":171,"body_text":172,"firm_name":173,"letter_id":174,"created_at":44,"fei_number":19,"letter_url":175,"updated_at":176,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":177,"product_type":49,"closeout_date":19,"issuing_office":82,"recipient_name":178,"body_fetched_at":179,"delivery_method":118,"recipient_title":19,"reference_number":180,"action_taken_date":181,"medical_device_id":19,"response_letter_date":19},1077,[35,169,170,82,83,13,13,13],"\u003Ctime datetime=\"2024-12-30T05:00:00Z\">12\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolutionary-biologics-inc-681586-12302024\">Evolutionary Biologics Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-24-681586\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jim Morrison\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Evolutionary Biologics Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14 Penn Plaza West 34th Street Floor 9\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10122\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:admin@evolutionarybiologics.com\"> admin@evolutionarybiologics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 30, 2024\u003C\u002Fp>\u003Cp>Warning Letter #: CBER-24-681586\u003C\u002Fp>\u003Cp>Dear Mr. Morrison:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has reviewed your company’s website at the internet address www.evolutionarybiologics.com\u002Frx (last visited November 2024), as well as other information available to the Agency. FDA has determined that you sell the following products in the United States: EXO RNA™ (exosome product), EVO JEL™ (an umbilical cord-derived product), and EVO HYBRID™ (a cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane) (collectively, “your products”). This letter is to advise you that your products are unapproved new drugs and are also unlicensed biological products. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website at www.evolutionarybiologics.com\u002Frx (last visited November 2024), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your website contains the following statements:\u003C\u002Fp>\u003Cp>\u003Cu>EVO JEL™\u003C\u002Fu>\u003Cbr>• “EVO JEL™ is especially effective in orthopedics because it provides cushioning and structural support for tissue and joints while addressing widespread inflammation and modulating an abnormal immune response.” • “EVO JEL™ … can be used as an alternative to assist with musculoskeletal injuries, ailments involving tissue and joints in both acute and chronic settings.”\u003Cbr>• “EVO JEL™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• Under “Advantages of EVO JEL™”, you list, “Decreases Inflammation” and “Non-surgical orthopedic option for patients”\u003Cbr>• Under “Applications of EVO JEL™”, you list, “Large joints (Knee, Hip, Shoulder &amp; Ankle)”…”Chronic partial rotator cuff tears”…”Persistent partial tendon tears (Tennis Elbow)”…”Plantar fasciitis\u002FBone Spurs”…”Quadriceps and patellar tendon tears”…”Muscular tears”…”Meniscus and cartilage tears”…”Intervertebral disc and spinal facet joints”…”Radicular and Sacroiliac nerves”…”Osteoarthritis”\u003C\u002Fp>\u003Cp>\u003Cu>EVO HYBRID™\u003C\u002Fu>\u003Cbr>• “EVO HYBRID helps restore and improve your internal wellness by reducing inflammation, regenerating tissue, lengthening telomeres, stimulating neuronal growth, modulating the immune response, and other important factors contributing to homeostasis, longevity, and quality of life.”\u003Cbr>• “EVO HYBRID™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• “SOME KEY GROWTH FACTORS PRESENT IN EVO HYBRID™...\u003Cbr>&nbsp; &nbsp; • “TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein; converts inflammatory T cells into anti-inflammatory regulatory T cells...\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • PDGF-AA: Regulates proliferation and migration of myocytes and supports angiogenesis\u003Cbr>&nbsp; &nbsp; • VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\u003Cbr>&nbsp; &nbsp; • TIMP -1 and 2 Tissue Inhibitor of Metallopeptidase 1 &amp; 2: Blocks Cartilage and Extracellular Matrix Degradation, Important for Cartilage Repair\u003Cbr>&nbsp; &nbsp; • IGF-1 Insulin-Like Growth Factor: Mediates many of the actions of GH, stimulates the growth of bones and other tissues...\u003Cbr>&nbsp; &nbsp; • B-NGF Beta Nerve Growth Factor: involved with the maintenance, growth and proliferation of target growth neurons”\u003C\u002Fp>\u003Cp>\u003Cu>EXO RNA™\u003C\u002Fu>\u003Cbr>• “Can EXO RNATM Benefit Neurodegenerative Diseases? Research has shown that MSC Exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, neuronal growth, and suppress inflammatory processes within the brain tissue.”&nbsp;&nbsp;\u003Cbr>• “NEUROBIOLOGICS; SOME KEY GROWTH FACTORS PRESENT IN EXO RNA™ . . .\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • PDGF-BB Platelet Derived Growth Factor Sub-Unit B: Growth factor used to stimulate healing in soft and hard tissues\u003Cbr>&nbsp; &nbsp; • VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\u003Cbr>&nbsp; &nbsp; • GDF-15 Growth Differentiation Factor 15: Regulates inflammation, apoptosis, cell repair, and growth\u003Cbr>&nbsp; &nbsp; • TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein. Converts inflammatory T cells into anti-inflammatory regulatory T cells...\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • MIP-1 Macrophage Inflammatory Protein 1: Also known as CC1-4, recruits mononuclear cells to the treatment area”\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your product derived from umbilical cord (EVO JEL™) and your cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane (EVO HYBRID™) are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, 42 U.S.C. 264, and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including applicable premarket review.\u003C\u002Fp>\u003Cp>Based on the review of the materials described above, your firm does not qualify for any exception in 21 CFR 1271.15, and your EVO JEL™ and EVO HYBRID™ products fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your umbilical cord derived product, EVO JEL™, fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” This product is not intended solely to perform the same basic function or functions of the umbilical cord in the recipient as in the donor, such as serving as a conduit. Rather, using this product for the treatment of diseases or conditions, such as inflammation, joint tears, tendon tears, muscle tears, cartilage tears, osteoarthritis, plantar fasciitis, and bone spurs is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\u003Cp>In addition, your umbilical cord derived product, EVO JEL™, fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord undergoes processing that alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. Information available to the Agency indicates that EVO JEL is offered in a “flowable” form. The processing of the umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because such processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>Additionally, EVO HYBRID™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord and amniotic membrane undergo processing that alters the original relevant characteristics of those tissues related to their utility for reconstruction, repair, or replacement. For example, the processing of umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because the processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form, and the processing of amniotic membrane from the form of a sheet into a flowable form alters the original relevant characteristics of the amniotic membrane relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength and elasticity.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>In addition, your product derived from umbilical cord, “placental tissue,” and amniotic membrane, EVO HYBRID™, fails to meet the criterion in 21 CFR 1271.10(a)(2) because this product is not intended solely to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, use of this product for reducing inflammation, tissue regeneration, organ regeneration, bone growth, tissue growth, cartilage repair, and wound healing, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\u003Cp>Therefore, these products are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your EVO JEL™ and EVO HYBRID™ products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Your exosome product, EXO RNA™, also meets the definition of a drug and biological product under section 201(g)(1) of the FD&amp;C Act and section 351(i) of the PHS Act, as discussed above, and is subject to premarket review and approval requirements. We direct your attention to FDA’s Public Safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fp>\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a BLA has been approved under section 351(a) is not required to have an approved application under section 505 of the FD&amp;C Act. 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your products are not the subject of an approved biologics license application (BLA) or an approved application under section 505 of the FD&amp;C Act. Based on our review, your products are both unapproved new drugs and unlicensed biological products, and you cause their introduction or delivery for introduction into interstate commerce in violation of section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This letter addresses certain issues regarding the above-described products and is not intended to be an all-inclusive review. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations. We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen working days, please explain the reason for the delay and the timeframe for completion. If you believe that your products are not in violation of the FD&amp;C Act or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>In addition, we have concerns with your products EXO RX, EXO ELIXIR™ and \u003Cstrong>EXO PERIO™\u003C\u002Fstrong>, which are other products described on your websites www.evolutionarybiologics.com\u002Frx and www.evobiologics.com. Your websites (last visited November 2024), make statements indicating these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the human body, for example:\u003Cbr>• “EXO RX™ expresses 30 forms of collagen and is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• Under “WHY EXO RX™…”, you list, “Anti-Fibrotic”… “Increases epidermal thickness and dermal collagen”…”Reduces scarring in cosmetic procedures and burns”…”Has been known to reduces [sic] acne”\u003Cbr>• “EXO ELIXIR is designed to regenerate your skin at a cellular level, with exceptional wound healing and anti-inflammatory growth factors that promote tissue engineering and regeneration.”\u003Cbr>• Under EXO ELIXIR “Advantages” you describe, “Modulating Inflammation…Promoting healing of wounds...”\u003Cbr>• “EVO PERIO™ Is a Wharton’s Jelly product rich with Mesenchymal Stem Cell exosomes. MSC exosomes induce bone, cartilage, dentin, mucosa, and pulp tissue formation while enhancing oral and craniofacial tissue engineering and regeneration.”&nbsp;\u003Cbr>• “EXO PERIO has demonstrated unique biological properties including being angiogenic, anti-inflammatory, antifibrotic, antimicrobial and immune privileged. The product has shown a strong tendency to accelerate healing and wound repair.\"\u003Cbr>• “Exo Perio can offer solutions for problems like craniofacial, osteochondral, periodontal tissue, nerve, pulp, or endodontics injuries.”\u003C\u002Fp>\u003Cp>FDA has not identified approved BLAs in effect for your EXO RX™, EXO ELIXIR™ and \u003Cstrong>EXO PERIO™\u003C\u002Fstrong> products. In your response, please explain the basis of your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\u003C\u002Fp>\u003Cp>Your response should be emailed to CBERDCMRecommendations@fda.hhs.gov. If you have any questions regarding this letter, please contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>Melissa J. Mendoza\u003Cbr>Director, Office of Compliance and Biologics Quality&nbsp;&nbsp;\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You market EVO HYBRID as being derived from “placental tissue,” in addition to umbilical cord and amniotic membrane. It is unclear what you mean by “placental tissue” in this context, as the mature placenta is composed of multiple tissues. Regardless, your EVO HYBRID product is regulated as a drug and biological product for the reasons described in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your EVO JEL™ and EVO HYBRID™ products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nReference #:\n\nCBER-24-681586\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJim Morrison\n\nRecipient Title\n\nCEO\n\nEvolutionary Biologics Inc.\n\n14 Penn Plaza West 34th Street Floor 9\n\nNew York, NY 10122\n\nUnited States\n\nadmin@evolutionarybiologics.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nDecember 30, 2024\nWarning Letter #: CBER-24-681586\nDear Mr. Morrison:\nThe United States Food and Drug Administration (FDA) has reviewed your company’s website at the internet address www.evolutionarybiologics.com\u002Frx (last visited November 2024), as well as other information available to the Agency. FDA has determined that you sell the following products in the United States: EXO RNA™ (exosome product), EVO JEL™ (an umbilical cord-derived product), and EVO HYBRID™ (a cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane) (collectively, “your products”). This letter is to advise you that your products are unapproved new drugs and are also unlicensed biological products. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website at www.evolutionarybiologics.com\u002Frx (last visited November 2024), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your website contains the following statements:\nEVO JEL™\n• “EVO JEL™ is especially effective in orthopedics because it provides cushioning and structural support for tissue and joints while addressing widespread inflammation and modulating an abnormal immune response.” • “EVO JEL™ … can be used as an alternative to assist with musculoskeletal injuries, ailments involving tissue and joints in both acute and chronic settings.”\n• “EVO JEL™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• Under “Advantages of EVO JEL™”, you list, “Decreases Inflammation” and “Non-surgical orthopedic option for patients”\n• Under “Applications of EVO JEL™”, you list, “Large joints (Knee, Hip, Shoulder & Ankle)”…”Chronic partial rotator cuff tears”…”Persistent partial tendon tears (Tennis Elbow)”…”Plantar fasciitis\u002FBone Spurs”…”Quadriceps and patellar tendon tears”…”Muscular tears”…”Meniscus and cartilage tears”…”Intervertebral disc and spinal facet joints”…”Radicular and Sacroiliac nerves”…”Osteoarthritis”\nEVO HYBRID™\n• “EVO HYBRID helps restore and improve your internal wellness by reducing inflammation, regenerating tissue, lengthening telomeres, stimulating neuronal growth, modulating the immune response, and other important factors contributing to homeostasis, longevity, and quality of life.”\n• “EVO HYBRID™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• “SOME KEY GROWTH FACTORS PRESENT IN EVO HYBRID™...\n• “TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein; converts inflammatory T cells into anti-inflammatory regulatory T cells...\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• PDGF-AA: Regulates proliferation and migration of myocytes and supports angiogenesis\n• VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\n• TIMP -1 and 2 Tissue Inhibitor of Metallopeptidase 1 & 2: Blocks Cartilage and Extracellular Matrix Degradation, Important for Cartilage Repair\n• IGF-1 Insulin-Like Growth Factor: Mediates many of the actions of GH, stimulates the growth of bones and other tissues...\n• B-NGF Beta Nerve Growth Factor: involved with the maintenance, growth and proliferation of target growth neurons”\nEXO RNA™\n• “Can EXO RNATM Benefit Neurodegenerative Diseases? Research has shown that MSC Exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, neuronal growth, and suppress inflammatory processes within the brain tissue.”\n• “NEUROBIOLOGICS; SOME KEY GROWTH FACTORS PRESENT IN EXO RNA™ . . .\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• PDGF-BB Platelet Derived Growth Factor Sub-Unit B: Growth factor used to stimulate healing in soft and hard tissues\n• VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\n• GDF-15 Growth Differentiation Factor 15: Regulates inflammation, apoptosis, cell repair, and growth\n• TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein. Converts inflammatory T cells into anti-inflammatory regulatory T cells...\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• MIP-1 Macrophage Inflammatory Protein 1: Also known as CC1-4, recruits mononuclear cells to the treatment area”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) 42 U.S.C. § 262(i).\nYour product derived from umbilical cord (EVO JEL™) and your cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane (EVO HYBRID™) are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, 42 U.S.C. 264, and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including applicable premarket review.\nBased on the review of the materials described above, your firm does not qualify for any exception in 21 CFR 1271.15, and your EVO JEL™ and EVO HYBRID™ products fail to meet all the criteria in 21 CFR 1271.10(a).\nFor example, your umbilical cord derived product, EVO JEL™, fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” This product is not intended solely to perform the same basic function or functions of the umbilical cord in the recipient as in the donor, such as serving as a conduit. Rather, using this product for the treatment of diseases or conditions, such as inflammation, joint tears, tendon tears, muscle tears, cartilage tears, osteoarthritis, plantar fasciitis, and bone spurs is not homologous use as defined in 21 CFR 1271.3(c).\nIn addition, your umbilical cord derived product, EVO JEL™, fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord undergoes processing that alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. Information available to the Agency indicates that EVO JEL is offered in a “flowable” form. The processing of the umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because such processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nAdditionally, EVO HYBRID™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord and amniotic membrane undergo processing that alters the original relevant characteristics of those tissues related to their utility for reconstruction, repair, or replacement. For example, the processing of umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because the processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form, and the processing of amniotic membrane from the form of a sheet into a flowable form alters the original relevant characteristics of the amniotic membrane relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength and elasticity.1\nIn addition, your product derived from umbilical cord, “placental tissue,” and amniotic membrane, EVO HYBRID™, fails to meet the criterion in 21 CFR 1271.10(a)(2) because this product is not intended solely to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, use of this product for reducing inflammation, tissue regeneration, organ regeneration, bone growth, tissue growth, cartilage repair, and wound healing, for example, is not homologous use as defined in 21 CFR 1271.3(c).\nTherefore, these products are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your EVO JEL™ and EVO HYBRID™ products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nYour exosome product, EXO RNA™, also meets the definition of a drug and biological product under section 201(g)(1) of the FD&C Act and section 351(i) of the PHS Act, as discussed above, and is subject to premarket review and approval requirements. We direct your attention to FDA’s Public Safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nTo lawfully market a drug that is a biological product, a valid biologics license must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a BLA has been approved under section 351(a) is not required to have an approved application under section 505 of the FD&C Act. 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your products are not the subject of an approved biologics license application (BLA) or an approved application under section 505 of the FD&C Act. Based on our review, your products are both unapproved new drugs and unlicensed biological products, and you cause their introduction or delivery for introduction into interstate commerce in violation of section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis letter addresses certain issues regarding the above-described products and is not intended to be an all-inclusive review. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations. We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen working days, please explain the reason for the delay and the timeframe for completion. If you believe that your products are not in violation of the FD&C Act or applicable regulations, include your reasoning and any supporting information for our consideration.\nIn addition, we have concerns with your products EXO RX, EXO ELIXIR™ and EXO PERIO™, which are other products described on your websites www.evolutionarybiologics.com\u002Frx and www.evobiologics.com. Your websites (last visited November 2024), make statements indicating these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the human body, for example:\n• “EXO RX™ expresses 30 forms of collagen and is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• Under “WHY EXO RX™…”, you list, “Anti-Fibrotic”… “Increases epidermal thickness and dermal collagen”…”Reduces scarring in cosmetic procedures and burns”…”Has been known to reduces [sic] acne”\n• “EXO ELIXIR is designed to regenerate your skin at a cellular level, with exceptional wound healing and anti-inflammatory growth factors that promote tissue engineering and regeneration.”\n• Under EXO ELIXIR “Advantages” you describe, “Modulating Inflammation…Promoting healing of wounds...”\n• “EVO PERIO™ Is a Wharton’s Jelly product rich with Mesenchymal Stem Cell exosomes. MSC exosomes induce bone, cartilage, dentin, mucosa, and pulp tissue formation while enhancing oral and craniofacial tissue engineering and regeneration.”\n• “EXO PERIO has demonstrated unique biological properties including being angiogenic, anti-inflammatory, antifibrotic, antimicrobial and immune privileged. The product has shown a strong tendency to accelerate healing and wound repair.\"\n• “Exo Perio can offer solutions for problems like craniofacial, osteochondral, periodontal tissue, nerve, pulp, or endodontics injuries.”\nFDA has not identified approved BLAs in effect for your EXO RX™, EXO ELIXIR™ and EXO PERIO™ products. In your response, please explain the basis of your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\nYour response should be emailed to CBERDCMRecommendations@fda.hhs.gov. If you have any questions regarding this letter, please contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\nMelissa J. Mendoza\nDirector, Office of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n______________________\n1 You market EVO HYBRID as being derived from “placental tissue,” in addition to umbilical cord and amniotic membrane. It is unclear what you mean by “placental tissue” in this context, as the mature placenta is composed of multiple tissues. Regardless, your EVO HYBRID product is regulated as a drug and biological product for the reasons described in this letter.\n2 Because your EVO JEL™ and EVO HYBRID™ products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Evolutionary Biologics Inc.","evolutionary-biologics-inc-681586-12302024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolutionary-biologics-inc-681586-12302024","2026-10-26T08:08:37.862855+00:00","681586","Jim Morrison","2026-08-19T17:03:23.375+00:00","CBER-24-681586","2024-12-30",{"id":183,"raw":184,"subject":84,"body_html":189,"body_text":190,"firm_name":191,"letter_id":192,"created_at":89,"fei_number":19,"letter_url":193,"updated_at":194,"action_type":22,"case_status":23,"posted_date":195,"marcs_cms_no":196,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":197,"body_fetched_at":198,"delivery_method":143,"recipient_title":19,"reference_number":199,"action_taken_date":200,"medical_device_id":19,"response_letter_date":19},899,[185,186,187,38,188,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-16T05:00:00Z\">12\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskye-biologics-holdings-llc-654466-12162024\">Skye Biologics Holdings LLC\u003C\u002Fa>","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-24-654466\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Christopher M.B. Sharp\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Skye Biologics Holdings LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2255 Campus Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>El Segundo\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90245-0001\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CBER-24-654466&nbsp;\u003C\u002Fp>\u003Cp>December 16, 2024&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Sharp:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at 2255 Campus Dr, El Segundo, CA 90245, between November 29, 2022 and December 9, 2022. During the inspection, FDA documented that your company manufactures “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioECM™ (collectively, “your products\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>”).&nbsp;\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. §355(a). Your introduction or delivery for introduction of your product[s] into interstatecommerce, or the causing thereof, is prohibited under sections 301(d) of the FD&amp;C Act,21 U.S.C. § 331(d). Your products are also unlicensed biological products in violation of section 351(a) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your adulterated products into interstate commerce is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA prior to, during, and\u002For after the inspection, including information on your website, www.skyebiologics.com, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your webpage for “Tissue Transplants Utilizing Extracellular Matrix Preservation (BioECM) Technology”, located at https:\u002F\u002Fwww.skyebiologics.com\u002Ftechnology, states that “Not all Placental Allografts are Created Equal… Placental tissues have been shown in the literature to be naturally anti-inflammatory, anti-fibrotic, anti-microbial, to modulate inflammation, promote tissue remodeling and reduce scar tissue formation in clinical applications.”\u003C\u002Fli>\u003Cli>In a press release regarding your BioECM product, you state that “FastActing Amniotic Membranes are part of HRT’s &amp; Skye’s extensive line of amniotic and placental products designed to help support proper tissue remodeling while modulating scarring and inflammation.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including, as applicable, premarket review. Based on a review of relevant materials, your company does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into a flowable form, drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended solely to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your products are intended for, e.g., modulation of inflammation and promotion of remodeling of tissues; anti-inflammatory, anti-fibrotic, and anti-microbial purposes; and supplementing or filling a void, which are not basic functions of umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, these products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant violations from CGMP requirements, including violations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR parts 210 and 211.\u003C\u002Fp>\u003Cp>At the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant violations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the November 2022 inspection, as discussed below.\u003C\u002Fp>\u003Cp>The CGMP violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. 21 CFR 211.100(a).\u003C\u002Fstrong> Specifically, your firm has not validated the manufacturing processes for your products with respect to identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area, 21 CFR 211.42(c)(10)(iv), as well as failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile. 21 CFR 211.113(b).\u003C\u002Fstrong> Your written procedures for environmental monitoring of your firm’s aseptic processing areas (e.g., laminar flow hoods) are not sufficient to detect problems and ensure low bioburden levels prior to sterilization. For example,\u003C\u002Fp>\u003Cp>a. You do not perform nonviable particulate monitoring or viable microbial \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring within your ISO 5 laminar flow hoods in association with all production shifts. You also do not conduct personnel monitoring of operators who perform processing of your products. Due to the higher risk of microbial contamination in this environment where open processing occurs, environmental monitoring inside the laminar flow hood should be conducted in association with each batch.\u003C\u002Fp>\u003Cp>b. Your ISO 5 laminar flow hoods, which are used for tissue cleaning, rinsing, and weighing, are located within an unclassified area. The area immediately adjacent to the critical processing areas should be controlled and monitored to minimize the level of potential contaminants in the final product.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure the components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality and purity. 21 CFR211.160(b).\u003C\u002Fstrong> For example, you have not established appropriate specifications to assure that your products conform to appropriate standards of identity, strength, &nbsp;quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to perform appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms.21 CFR 211.165(b).\u003C\u002Fstrong> Specifically, you failed to perform endotoxin testing on final product batches. Such laboratory testing is necessary as your products are purported to be sterile.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. 21 CFR 211.192. \u003C\u002Fstrong>For example, from January 2021 to August 2022, you failed to investigate three action-level excursions for environmental monitoring observed in the a septic processing area (e.g., laminar flow hoods).\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure to prepare batch production and control records that document each significant step in the manufacture, processing, packing, or holding of your umbilical cord blood products. 21 CFR 211.188(b).\u003C\u002Fstrong> Specifically, your batch production records do not include documentation of the accomplishment of each significant step in the manufacture of your products or the person(s) performing each of those steps, for example:\u003C\u002Fp>\u003Cp>a. The weight of, for e.g., umbilical cord tissue used in processing.\u003C\u002Fp>\u003Cp>b. The amount of saline used to formulate the final product.\u003C\u002Fp>\u003Cp>c. Processing of tissue in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine, including weight of tissue processed, machine operational parameters, run time, and the number of runs completed.\u003C\u002Fp>\u003Cp>d. Identification of equipment, such as laminar flow hoods, used in processing.\u003C\u002Fp>\u003Cp>\u003Cstrong>7. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates. 21 CFR 211.166(a).\u003C\u002Fstrong> Specifically, your firm has assigned a five-year expiration date for your products without supporting data regarding the stability characteristics of the products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge receipt of your letter received on January 3, 2023, which provides a response to FDA’s inspectional observations (FDA-483). We have reviewed the represented corrective actions outlined in the response, and these actions are not adequate to address the above-noted violations. For example, your response does not address your firm’s continued manufacture and distribution of your products or your plans for disposition of your current inventory manufactured under the violative conditions outlined above.\u003C\u002Fp>\u003Cp>Your firm’s response repeatedly asserts that your products should be regulated solely under section 361 of the PHS Act, and that the violations noted above are not applicable to your products. Based on your position, you have not proposed corrective actions which address the CGMP violations noted above. While you assert that your products should be regulated solely under section 361 of the PHS Act, as explained above, the available evidence shows that your products do not meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271.\u003C\u002Fp>\u003Cp>As such, your response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we have concerns with your “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioRenew™, and products derived from amniotic and chorionic membrane and umbilical cord, namely HRT® BioPower-A, HRT® BioPower-C, and HRT® NX. In your response, please explain the basis for your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.&nbsp;\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure that your establishment is in full compliance with the law.&nbsp;\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions may include seizure and\u002For injunction.&nbsp;\u003C\u002Fp>\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent any violations, or similar violations, from occurring again. Include any documentation necessary to show that these matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You market your BioECM™ products as BioECM ActiveMatrix®, BioECM BurnMatrix®, BioECM CryoMatrix®, BioECM MX™, BioECM NX™, BioECM RX, BioECM WoundEx™.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all of the other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nCBER-24-654466\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nChristopher M.B. Sharp\n\nRecipient Title\n\nChief Executive Officer\n\nSkye Biologics Holdings LLC\n\n2255 Campus Dr\n\nEl Segundo, CA 90245-0001\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nCBER-24-654466\nDecember 16, 2024\nDear Mr. Sharp:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at 2255 Campus Dr, El Segundo, CA 90245, between November 29, 2022 and December 9, 2022. During the inspection, FDA documented that your company manufactures “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioECM™ (collectively, “your products1”).\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §355(a). Your introduction or delivery for introduction of your product[s] into interstatecommerce, or the causing thereof, is prohibited under sections 301(d) of the FD&C Act,21 U.S.C. § 331(d). Your products are also unlicensed biological products in violation of section 351(a) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your adulterated products into interstate commerce is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA prior to, during, and\u002For after the inspection, including information on your website, www.skyebiologics.com, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\nYour webpage for “Tissue Transplants Utilizing Extracellular Matrix Preservation (BioECM) Technology”, located at https:\u002F\u002Fwww.skyebiologics.com\u002Ftechnology, states that “Not all Placental Allografts are Created Equal… Placental tissues have been shown in the literature to be naturally anti-inflammatory, anti-fibrotic, anti-microbial, to modulate inflammation, promote tissue remodeling and reduce scar tissue formation in clinical applications.”\nIn a press release regarding your BioECM product, you state that “FastActing Amniotic Membranes are part of HRT’s & Skye’s extensive line of amniotic and placental products designed to help support proper tissue remodeling while modulating scarring and inflammation.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including, as applicable, premarket review. Based on a review of relevant materials, your company does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into a flowable form, drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended solely to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your products are intended for, e.g., modulation of inflammation and promotion of remodeling of tissues; anti-inflammatory, anti-fibrotic, and anti-microbial purposes; and supplementing or filling a void, which are not basic functions of umbilical cord in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, these products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nAdditionally, during the inspection, FDA investigators documented evidence of significant violations from CGMP requirements, including violations from section 501(a)(2)(B) of the FD&C Act and 21 CFR parts 210 and 211.\nAt the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant violations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the November 2022 inspection, as discussed below.\nThe CGMP violations include, but are not limited to, the following:\n1. Failure to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. 21 CFR 211.100(a). Specifically, your firm has not validated the manufacturing processes for your products with respect to identity, strength, quality, and purity.\n2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area, 21 CFR 211.42(c)(10)(iv), as well as failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile. 21 CFR 211.113(b). Your written procedures for environmental monitoring of your firm’s aseptic processing areas (e.g., laminar flow hoods) are not sufficient to detect problems and ensure low bioburden levels prior to sterilization. For example,\na. You do not perform nonviable particulate monitoring or viable microbial (b)(4) monitoring within your ISO 5 laminar flow hoods in association with all production shifts. You also do not conduct personnel monitoring of operators who perform processing of your products. Due to the higher risk of microbial contamination in this environment where open processing occurs, environmental monitoring inside the laminar flow hood should be conducted in association with each batch.\nb. Your ISO 5 laminar flow hoods, which are used for tissue cleaning, rinsing, and weighing, are located within an unclassified area. The area immediately adjacent to the critical processing areas should be controlled and monitored to minimize the level of potential contaminants in the final product.\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure the components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality and purity. 21 CFR211.160(b). For example, you have not established appropriate specifications to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\n4. Failure to perform appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms.21 CFR 211.165(b). Specifically, you failed to perform endotoxin testing on final product batches. Such laboratory testing is necessary as your products are purported to be sterile.\n5. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. 21 CFR 211.192. For example, from January 2021 to August 2022, you failed to investigate three action-level excursions for environmental monitoring observed in the a septic processing area (e.g., laminar flow hoods).\n6. Failure to prepare batch production and control records that document each significant step in the manufacture, processing, packing, or holding of your umbilical cord blood products. 21 CFR 211.188(b). Specifically, your batch production records do not include documentation of the accomplishment of each significant step in the manufacture of your products or the person(s) performing each of those steps, for example:\na. The weight of, for e.g., umbilical cord tissue used in processing.\nb. The amount of saline used to formulate the final product.\nc. Processing of tissue in the (b)(4) machine, including weight of tissue processed, machine operational parameters, run time, and the number of runs completed.\nd. Identification of equipment, such as laminar flow hoods, used in processing.\n7. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates. 21 CFR 211.166(a). Specifically, your firm has assigned a five-year expiration date for your products without supporting data regarding the stability characteristics of the products.\nResponse to the Form FDA-483\nWe acknowledge receipt of your letter received on January 3, 2023, which provides a response to FDA’s inspectional observations (FDA-483). We have reviewed the represented corrective actions outlined in the response, and these actions are not adequate to address the above-noted violations. For example, your response does not address your firm’s continued manufacture and distribution of your products or your plans for disposition of your current inventory manufactured under the violative conditions outlined above.\nYour firm’s response repeatedly asserts that your products should be regulated solely under section 361 of the PHS Act, and that the violations noted above are not applicable to your products. Based on your position, you have not proposed corrective actions which address the CGMP violations noted above. While you assert that your products should be regulated solely under section 361 of the PHS Act, as explained above, the available evidence shows that your products do not meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271.\nAs such, your response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent.\nAdditional Concerns\nIn addition, we have concerns with your “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioRenew™, and products derived from amniotic and chorionic membrane and umbilical cord, namely HRT® BioPower-A, HRT® BioPower-C, and HRT® NX. In your response, please explain the basis for your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure that your establishment is in full compliance with the law.\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions may include seizure and\u002For injunction.\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent any violations, or similar violations, from occurring again. Include any documentation necessary to show that these matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n__________________________\n1 You market your BioECM™ products as BioECM ActiveMatrix®, BioECM BurnMatrix®, BioECM CryoMatrix®, BioECM MX™, BioECM NX™, BioECM RX, BioECM WoundEx™.\n2 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all of the other criteria in 21 CFR 1271.10(a).","Skye Biologics Holdings LLC","skye-biologics-holdings-llc-654466-12162024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskye-biologics-holdings-llc-654466-12162024","2026-10-26T08:09:58.907333+00:00","2025-05-20","654466","Christopher M.B. Sharp","2026-08-19T16:46:38.883+00:00","CBER-24-654466","2024-12-16",{"id":202,"raw":203,"subject":84,"body_html":208,"body_text":209,"firm_name":210,"letter_id":211,"created_at":212,"fei_number":19,"letter_url":213,"updated_at":214,"action_type":22,"case_status":23,"posted_date":215,"marcs_cms_no":216,"product_type":49,"closeout_date":19,"issuing_office":207,"recipient_name":217,"body_fetched_at":218,"delivery_method":219,"recipient_title":19,"reference_number":19,"action_taken_date":220,"medical_device_id":19,"response_letter_date":19},2854,[204,205,206,207,83,13,13,13],"\u003Ctime datetime=\"2022-02-22T14:20:00Z\">02\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-02T05:00:00Z\">02\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmart-surgical-inc-dba-burst-biologics-614361-02022022\">Smart Surgical, Inc dba Burst Biologics\u003C\u002Fa>","Office of Biological Products Operations – Division 2","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Christopher D. Jones\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Smart Surgical, Inc dba Burst Biologics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3501 W. Elder St., Ste. 104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boise\u003C\u002Fspan>, \u003Cspan>ID\u003C\u002Fspan> \u003Cspan>83705\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 2, 2022\u003C\u002Fp>\n\n\u003Cp>[OBPO 21-614361]\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jones:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Smart Surgical, Inc., dba Burst Biologics (hereinafter, Burst Biologics), located at 3501 W. Elder St., Ste. 104, Boise, ID 83705, conducted between February 22, 2021 and March 5, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human umbilical cord blood, namely, BioBurst Fluid and BioBurst Rejuv, for allogeneic use. You distribute your products to health care providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and during the inspection, including information on the Burst Biologics website, burstbiologics.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Burst Biologics does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from human umbilical cord blood fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” Your umbilical cord blood derived products are not intended to perform the same basic function or functions of the umbilical cord blood in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system. Rather, your products are intended to be applied to surgical and injury sites to supplement tissue defects and for orthopedic use, and your products could be administered via intra-articular injection. Using your umbilical cord blood derived products in this manner is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>In addition, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(4) because they are manufactured from allogeneic umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function, and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\u003C\u002Fp>\n\n\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because these HCT\u002FPs do not meet all the criteria in 21 CFR 1271.10(a), and Burst Biologics does not qualify for any exception in 21 CFR 1271.15, the products are regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your HCT\u002FPs derived from human umbilical cord blood are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Part 1271. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant deviations from CGMP and CGTP requirements applicable to your products. These deficiencies include, but are not limited to, the following:\u003Cbr>\n\u003Cbr>\n\u003Cstrong>1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)].\u003C\u002Fstrong> FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent or disease (RCDAD) under 21 CFR 1271.3(r)(2). Since ZIKV is a RCDAD, donors of umbilical cord, blood, placenta or other gestational tissues should be considered ineligible if certain risk factors are present. However, in May 2016, you began receiving umbilical cord blood units recovered from allogeneic donors in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an area considered at increased risk for ZIKV, and you failed to determine these donors as ineligible. These umbilical cord blood units were manufactured into BioBurst Fluid and BioBurst Rejuv and distributed throughout the United States. Although you have since developed new procedures that provide for assessing eligibility based on ZIKV, your prior deficiencies raise potentially significant safety concerns.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> Your firm failed to adequately validate the aseptic process used to manufacture BioBurst Fluid and BioBurst Rejuv (i.e., by performing media fill simulations) since manufacturing began in December 2015. Since then, your firm manufactured and distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of BioBurst Fluid and BioBurst Rejuv. These products purport to be sterile. More specifically:\u003C\u002Fp>\n\n\u003Cp>a. Prior to October 31, 2019, you did not conduct any media fill simulations to validate the aseptic manufacturing process for BioBurst Fluid and BioBurst Rejuv to demonstrate that your aseptic process can consistently produce products free of viable microorganisms.\u003C\u002Fp>\n\n\u003Cp>b. On October 31, 2019, a validation plan (VAL-PR-UCB Product Manufacturing-003) under which media fill simulations were conducted to validate your aseptic process for BioBurst Fluid and BioBurst Rejuv was approved; however, the media fills performed under this plan are inadequate\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. For example, the units produced during your media fill simulations were not incubated under conditions adequate to detect microorganisms that might otherwise be difficult to culture. Media fill samples were only incubated for \u003Cstrong>(b)(4)\u003C\u002Fstrong> days.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> Your firm has not established an adequate system for environmental, including personnel, monitoring in the aseptic processing areas where BioBurst Fluid and BioBurst Rejuv are manufactured. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm does not investigate personnel monitoring excursions that exceed your action limit. Approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of product associated with personnel monitoring excursions that were not investigated were distributed since October 2020.\u003C\u002Fp>\n\n\u003Cp>b. Your environmental monitoring procedure describes that up to and including \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>colony forming units (CFUs) is an acceptable result for a single personnel monitoring sample, including a sample from glove fingertips that enter the ISO-5 classified biological safety cabinet (BSC) where aseptic processing is conducted. We note that the current industry standard is &lt;1 CFU\u002Fplate for gloves or sleeves that enter the ISO-5 classified area and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for gowning that remains in the ISO-7 classified area. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potential significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)].\u003C\u002Fstrong> Specifically, you told our investigator that components utilized within UCB (umbilical cord blood) manufacturing are not sampled and tested prior to being used in production.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].\u003C\u002Fstrong> Specifically, since December 2015, your firm has had numerous sterility failures for batches of BioBurst Fluid and BioBurst Rejuv that you failed to investigate to determine the source of the contamination beyond identifying organisms (for example, a \u003Cem>Paenibacillus\u003C\u002Fem> species, \u003Cem>Bacillus\u003C\u002Fem> non-anthracis, \u003Cem>Kocuria rhizophila\u003C\u002Fem>,&nbsp;\u003Cem>Staphylococcus hominis\u003C\u002Fem>, and \u003Cem>Micrococcus luteus\u003C\u002Fem>) for a subset of these failed batches. For over 80% of the failures, you did not identify the contaminating microorganism(s). Since December 2015, your firm manufactured and distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of BioBurst Fluid and BioBurst Rejuv.\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we also note that we are concerned that you may not have verified the suitability of your sterility test method, that you represent is based on USP &lt;71&gt;, used for final product release testing of BioBurst Fluid and BioBurst Rejuv batches from December 2015 until July 31, 2020. Numerous BioBurst Fluid and BioBurst Rejuv batches remain within expiry. Please be reminded that you are required to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods employed, in accordance with 21 CFR 211.165(e).\u003Cbr>\n\u003Cbr>\nWe acknowledge receipt of your correspondences, dated April 16, 2021 and May 14, 2021, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. The responses to many of the observations do not provide sufficient detail to fully assess the adequacy of your corrective actions to date, lack a timeline for completion of all necessary corrective actions, and lack documentation to demonstrate that you have corrected your violations. Additionally, your responses are unsatisfactory in that they do not address your firm’s manufacture and distribution of your products derived from umbilical cord blood under the violative conditions outlined above. Nor do your responses remedy the above-noted violations.\u003C\u002Fp>\n\n\u003Cp>While you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>cc\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We also found no indication that the media used in your media fill simulation was demonstrated to promote growth of organisms pre- or post-incubation of media-filled units. Growth promotion of each batch of media should be performed to demonstrate the media is capable of detecting microorganisms. Furthermore, the October 2019 study was the only executed media fill simulation provided to FDA during the inspection. We recommend that routine media fill simulations be conducted semi-annually to evaluate the state of control of the aseptic process.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMr. Christopher D. Jones\n\nRecipient Title\n\nChief Executive Officer\n\nSmart Surgical, Inc dba Burst Biologics\n\n3501 W. Elder St., Ste. 104\n\nBoise, ID 83705\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nFebruary 2, 2022\n\n[OBPO 21-614361]\n\nDear Mr. Jones:\n\nDuring an inspection of your firm, Smart Surgical, Inc., dba Burst Biologics (hereinafter, Burst Biologics), located at 3501 W. Elder St., Ste. 104, Boise, ID 83705, conducted between February 22, 2021 and March 5, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human umbilical cord blood, namely, BioBurst Fluid and BioBurst Rejuv, for allogeneic use. You distribute your products to health care providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and during the inspection, including information on the Burst Biologics website, burstbiologics.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBurst Biologics does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from human umbilical cord blood fail to meet all the criteria in 21 CFR 1271.10(a).\n\nSpecifically, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” Your umbilical cord blood derived products are not intended to perform the same basic function or functions of the umbilical cord blood in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system. Rather, your products are intended to be applied to surgical and injury sites to supplement tissue defects and for orthopedic use, and your products could be administered via intra-articular injection. Using your umbilical cord blood derived products in this manner is not homologous use as defined in 21 CFR 1271.3(c).\n\nIn addition, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(4) because they are manufactured from allogeneic umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function, and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\n\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because these HCT\u002FPs do not meet all the criteria in 21 CFR 1271.10(a), and Burst Biologics does not qualify for any exception in 21 CFR 1271.15, the products are regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your HCT\u002FPs derived from human umbilical cord blood are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Part 1271. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\n\nAt the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant deviations from CGMP and CGTP requirements applicable to your products. These deficiencies include, but are not limited to, the following:\n\n1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)]. FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent or disease (RCDAD) under 21 CFR 1271.3(r)(2). Since ZIKV is a RCDAD, donors of umbilical cord, blood, placenta or other gestational tissues should be considered ineligible if certain risk factors are present. However, in May 2016, you began receiving umbilical cord blood units recovered from allogeneic donors in (b)(4), an area considered at increased risk for ZIKV, and you failed to determine these donors as ineligible. These umbilical cord blood units were manufactured into BioBurst Fluid and BioBurst Rejuv and distributed throughout the United States. Although you have since developed new procedures that provide for assessing eligibility based on ZIKV, your prior deficiencies raise potentially significant safety concerns.\n\n2. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. Your firm failed to adequately validate the aseptic process used to manufacture BioBurst Fluid and BioBurst Rejuv (i.e., by performing media fill simulations) since manufacturing began in December 2015. Since then, your firm manufactured and distributed approximately (b)(4) units of BioBurst Fluid and BioBurst Rejuv. These products purport to be sterile. More specifically:\n\na. Prior to October 31, 2019, you did not conduct any media fill simulations to validate the aseptic manufacturing process for BioBurst Fluid and BioBurst Rejuv to demonstrate that your aseptic process can consistently produce products free of viable microorganisms.\n\nb. On October 31, 2019, a validation plan (VAL-PR-UCB Product Manufacturing-003) under which media fill simulations were conducted to validate your aseptic process for BioBurst Fluid and BioBurst Rejuv was approved; however, the media fills performed under this plan are inadequate1. For example, the units produced during your media fill simulations were not incubated under conditions adequate to detect microorganisms that might otherwise be difficult to culture. Media fill samples were only incubated for (b)(4) days.\n\n3. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]. Your firm has not established an adequate system for environmental, including personnel, monitoring in the aseptic processing areas where BioBurst Fluid and BioBurst Rejuv are manufactured. For example:\n\na. Your firm does not investigate personnel monitoring excursions that exceed your action limit. Approximately (b)(4) units of product associated with personnel monitoring excursions that were not investigated were distributed since October 2020.\n\nb. Your environmental monitoring procedure describes that up to and including (b)(4) colony forming units (CFUs) is an acceptable result for a single personnel monitoring sample, including a sample from glove fingertips that enter the ISO-5 classified biological safety cabinet (BSC) where aseptic processing is conducted. We note that the current industry standard is \u003C1 CFU\u002Fplate for gloves or sleeves that enter the ISO-5 classified area and (b)(4) for gowning that remains in the ISO-7 classified area. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potential significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.\n\n4. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)]. Specifically, you told our investigator that components utilized within UCB (umbilical cord blood) manufacturing are not sampled and tested prior to being used in production.\n\n5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192]. Specifically, since December 2015, your firm has had numerous sterility failures for batches of BioBurst Fluid and BioBurst Rejuv that you failed to investigate to determine the source of the contamination beyond identifying organisms (for example, a Paenibacillus species, Bacillus non-anthracis, Kocuria rhizophila, Staphylococcus hominis, and Micrococcus luteus) for a subset of these failed batches. For over 80% of the failures, you did not identify the contaminating microorganism(s). Since December 2015, your firm manufactured and distributed approximately (b)(4) units of BioBurst Fluid and BioBurst Rejuv.\n\nIn addition to the above violations, we also note that we are concerned that you may not have verified the suitability of your sterility test method, that you represent is based on USP \u003C71>, used for final product release testing of BioBurst Fluid and BioBurst Rejuv batches from December 2015 until July 31, 2020. Numerous BioBurst Fluid and BioBurst Rejuv batches remain within expiry. Please be reminded that you are required to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods employed, in accordance with 21 CFR 211.165(e).\n\nWe acknowledge receipt of your correspondences, dated April 16, 2021 and May 14, 2021, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. The responses to many of the observations do not provide sufficient detail to fully assess the adequacy of your corrective actions to date, lack a timeline for completion of all necessary corrective actions, and lack documentation to demonstrate that you have corrected your violations. Additionally, your responses are unsatisfactory in that they do not address your firm’s manufacture and distribution of your products derived from umbilical cord blood under the violative conditions outlined above. Nor do your responses remedy the above-noted violations.\n\nWhile you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\ncc\n\n(b)(6)\n\n_______________________________\n\n1 We also found no indication that the media used in your media fill simulation was demonstrated to promote growth of organisms pre- or post-incubation of media-filled units. Growth promotion of each batch of media should be performed to demonstrate the media is capable of detecting microorganisms. Furthermore, the October 2019 study was the only executed media fill simulation provided to FDA during the inspection. We recommend that routine media fill simulations be conducted semi-annually to evaluate the state of control of the aseptic process.","Smart Surgical, Inc dba Burst Biologics","smart-surgical-inc-dba-burst-biologics-614361-02022022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmart-surgical-inc-dba-burst-biologics-614361-02022022","2026-10-26T08:09:59.293166+00:00","2022-02-22","614361","Mr. Christopher D. Jones","2026-08-20T02:09:59.584+00:00","VIA UNITED PARCEL SERVICE","2022-02-02",{"id":222,"raw":223,"subject":84,"body_html":227,"body_text":228,"firm_name":229,"letter_id":230,"created_at":44,"fei_number":19,"letter_url":231,"updated_at":232,"action_type":22,"case_status":23,"posted_date":233,"marcs_cms_no":19,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":234,"body_fetched_at":235,"delivery_method":143,"recipient_title":19,"reference_number":236,"action_taken_date":237,"medical_device_id":19,"response_letter_date":19},1305,[224,225,226,38,83,13,13,13],"\u003Ctime datetime=\"2024-08-27T13:20:00Z\">08\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-28T04:00:00Z\">06\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fberkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo\">Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 676984\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mesfin Mengesha\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>880 Harbour Way S., Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Richmond\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94804\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 28, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mengesha:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Berkeley Biologics, LLC, (operating during the inspection as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.), located at 880 Harbour Way S., Suite 100, Richmond, CA 94804, conducted between September 05, 2023 and September 25, 2023, the United States Food and Drug Administration (FDA) documented your manufacture of viable bone matrix products derived from human bone tissue and marketed as Viable Bone Matrix (VBM), Fiber Viable Bone Matrix (FVBM), Cellular Fiber Matrix (CFM)\u002FExcel Viable Bone Matrix (EFM),\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and Osteo Viable Bone Matrix (OVM). You have distributed these products throughout the United States to medical facilities. You intend these products to be used in orthopedic or reconstructive bone grafting procedures for bone repair and regeneration, and you purport them to be sterile.\u003C\u002Fp>\n\n\u003Cp>Human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and\u002For the Public Health Service Act (PHS Act) [42 U.S.C. § 262], and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Your products do not qualify for any exception in 21 CFR 1271.15, and your VBM, CFM\u002FEFM, and OVM products fail to meet all the criteria in 21 CFR 1271.10(a). Specifically, VBM, CFM\u002FEFM, and OVM fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of cartilage relating to its utility to perform its load-bearing and other physical functions, which generally include firmness, smoothness, flexibility, and resistance to deformation.\u003C\u002Fp>\n\n\u003Cp>Your products also fail to meet the criterion under 21 CFR 1271.10(a)(3) that the manufacture of the HCT\u002FP does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent. Your VBM, CFM, and OVM products are a combination of bone (cancellous and cortical) and another article, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Therefore, these three products – VBM, CFM\u002FEFM, and OVM – are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because these products do not meet all the criteria in 21 CFR 1271.10(a), and you do not qualify for any exception in 21 CFR 1271.15, these products are regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\u003C\u002Fp>\n\n\u003Cp>Be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR 312]. None of your products are the subject of an approved BLA, nor is there an IND in effect for any of them. Based on our review, these products are unapproved new drugs that you are introducing or delivering for introduction into interstate commerce in violation of sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act and section 351(a)(1) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented significant deviations from current good tissue practice (CGTP) requirements, including deviations from 21 CFR 1271, for FVBM and OVM. Upon further review of information collected during the inspection, FDA also identified significant deviations from current good manufacturing practice (CGMP) requirements for VBM, CFM\u002FEFM, and OVM, including section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP requirements, your VBM, CFM\u002FEFM, and OVM drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)], your introduction or delivery for introduction into interstate commerce of these three drug products is a prohibited act.\u003C\u002Fp>\n\n\u003Cp>Your CGTP deviations for your FVBM and OVM products manufactured between January 2022 and June 2023, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)].\u003C\u002Fstrong> For example, you failed to determine as ineligible \u003Cstrong>(b)(4)\u003C\u002Fstrong> deceased donors who have a documented medical diagnosis of sepsis. As discussed in the 2007 \u003Cem>Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\u002FPs)\u003C\u002Fem> (2007 DE Guidance), donor screening to reduce the risk of transmission of disease agents associated with sepsis is required. Tissues from these donors were manufactured into FVBM and OVM, and distributed for implantation into patients\u002Frecipients, some of which were associated with an outbreak of \u003Cem>Mycobacterium tuberculosis\u003C\u002Fem> infections. It appears this is a systemic issue not limited to these \u003Cstrong>(b)(4)\u003C\u002Fstrong> donors or products because this violation resulted from you following your SOP-0006 \u003Cem>Donor Eligibility Determination Criteria\u003C\u002Fem>, which does not require you to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, sepsis.\u003C\u002Fp>\n\n\u003Cp>We have received and reviewed your written responses, dated October 14, 2023, and November 30, 2023, to FDA’s inspectional observations on the Form FDA-483. The corrective actions described in your response are not adequate to address the above noted violation that was on the FDA-483.\u003C\u002Fp>\n\n\u003Cp>In your October response, you provided your revised procedure, \u003Cem>SOP-006 Donor Eligibility Determination Criteria\u003C\u002Fem> (as Attachment 2.2). Your “Donor Screening Guidance Document” in Attachment 2.2 and the revised sepsis algorithm in SOP-0006 do not determine as ineligible, donors who have a documented medical diagnosis of sepsis. Sepsis is a relevant communicable disease agent and disease (RCDAD) under 1271.3(r)(2), as described in the 2007 DE Guidance. Under 1271.75(d)(1), you must determine as ineligible a donor who is identified as having a risk factor for or clinical evidence of any RCDAD. You should revise Berkeley’s Donor Screening Guidance Document for sepsis and revise your sepsis algorithm in SOP-0006 so that these documents are compliant with 1271.75(d)(1).\u003C\u002Fp>\n\n\u003Cp>This donor eligibility issue applies across your products, including those regulated solely under section 361 of the PHS Act. Based on information available to FDA, you have received tissues from at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> donors who have sepsis documented in their medical records. We request that you provide us a list of all donors that have had risk factors for or clinical evidence of sepsis that you have determined to be eligible along with the products you have manufactured and distributed from these donors.\u003C\u002Fp>\n\n\u003Cp>Your CGMP deviations for VBM, CFM\u002FEFM, and OVM manufactured between January 2022 and June 2023, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example,\u003C\u002Fp>\n\n\u003Cp>a. According to your Process Qualification Reports (dated January 17, 2017, March 16, 2020, and April 7, 2023), you only required \u003Cstrong>(b)(4)\u003C\u002Fstrong> donors to meet your process qualification acceptance criteria even if some donor batches in the validation\u002Fqualification failed to meet the criteria. For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> OVM donor batches failed to meet your acceptance criteria, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> donor batches failed to meet your acceptance criteria for sterility testing.\u003C\u002Fp>\n\n\u003Cp>b. You have not validated the manufacturing processes for VBM, CFM\u002FEFM, and OVM with respect to identity, strength, quality, and purity. Your Process Qualification Reports document product bioburden testing, sterility testing, environmental and personnel monitoring, and in some cases \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, as the only tests included in your acceptance criteria. These tests are inadequate to assure the identity, strength, quality, and purity of these products.\u003C\u002Fp>\n\n\u003Cp>Based on our review of the “retrospective validation addendums” you provided in your November 2023 response, you have not addressed the issues noted above. For example, your validations continue to focus on sterility assurance controls, rather than identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to have an adequate system necessary to prevent contamination or mix-ups during aseptic processing [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your action limits for microbiological monitoring (i.e., active viable air and surface samples) within the critical area (i.e., inside the Biological Safety Cabinet (BSC)) were observed to be greater than \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs). Such high numbers of microorganisms can contribute to product contamination and pose a potentially significant safety concern.\u003C\u002Fp>\n\n\u003Cp>b. You do not perform sampling of critical surfaces in the BSC for microorganisms in association with each production batch.\u003C\u002Fp>\n\n\u003Cp>c. Your personnel monitoring sample locations are inadequate for personnel performing aseptic processing. For example, your firm does not conduct personnel monitoring of the forearms\u002Fsleeves of operators working in the BSC where your products are aseptically processed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish laboratory controls that include scientifically sound and appropriate specifications and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not established scientifically sound and appropriate specifications and test procedures to assure that VBM, CFM\u002FEFM, and OVM conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing, which is inadequate to measure appropriate standards of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. Sterility samples of VBM, CFM\u002FEFM, and OVM are frozen prior to sterility testing. Freezing product has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\u003C\u002Fp>\n\n\u003Cp>In your responses, you have committed to stopping the manufacture and distribution of all viable bone matrix products until, you state, you have met, “FDA’s standards for tissue processing validation.” However, you have not addressed the products manufactured under the violative conditions described above that remain on the market and available for implantation nor have you addressed the above CGMP violations. We acknowledge that the above CGMP violations were not included in the FDA-483; we expect you to address them in response to this letter.\u003C\u002Fp>\n\n\u003Cp>Additionally, your response fails to address your failure to have an IND in effect to study your VBM, CFM\u002FEFM, and OVM products or your lack of an approved BLA to lawfully market these products.\u003C\u002Fp>\n\n\u003Cp>Please also be advised that FDA has conducted a preliminary review of your HCT\u002FP, Fiber Viable Bone Matrix (FVBM). Based on the limited information available to FDA, we do not have a basis at this time for concluding that the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271 are met for Berkeley Biologics’ FVBM allogeneic HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure that your establishment is in full compliance with applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you believe that your products are not in violation of the FD&amp;C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion.\u003C\u002Fp>\n\n\u003Cp>Your response to this letter should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nKarlton Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations - Division 2\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\n\u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that the product name was changed from Excel Fiber Matrix to Cellular Fiber Matrix on April 21, 2023.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nOBPO 676984\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMesfin Mengesha\n\nRecipient Title\n\nChief Executive Officer\n\nBerkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.\n\n880 Harbour Way S., Suite 100\n\nRichmond, CA 94804\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nJune 28, 2024\n\nDear Mr. Mengesha:\n\nDuring an inspection of your firm, Berkeley Biologics, LLC, (operating during the inspection as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.), located at 880 Harbour Way S., Suite 100, Richmond, CA 94804, conducted between September 05, 2023 and September 25, 2023, the United States Food and Drug Administration (FDA) documented your manufacture of viable bone matrix products derived from human bone tissue and marketed as Viable Bone Matrix (VBM), Fiber Viable Bone Matrix (FVBM), Cellular Fiber Matrix (CFM)\u002FExcel Viable Bone Matrix (EFM),1 and Osteo Viable Bone Matrix (OVM). You have distributed these products throughout the United States to medical facilities. You intend these products to be used in orthopedic or reconstructive bone grafting procedures for bone repair and regeneration, and you purport them to be sterile.\n\nHuman cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and\u002For the Public Health Service Act (PHS Act) [42 U.S.C. § 262], and are subject to additional regulation, including appropriate premarket review.\n\nYour products do not qualify for any exception in 21 CFR 1271.15, and your VBM, CFM\u002FEFM, and OVM products fail to meet all the criteria in 21 CFR 1271.10(a). Specifically, VBM, CFM\u002FEFM, and OVM fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of cartilage relating to its utility to perform its load-bearing and other physical functions, which generally include firmness, smoothness, flexibility, and resistance to deformation.\n\nYour products also fail to meet the criterion under 21 CFR 1271.10(a)(3) that the manufacture of the HCT\u002FP does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent. Your VBM, CFM, and OVM products are a combination of bone (cancellous and cortical) and another article, (b)(4).\n\nTherefore, these three products – VBM, CFM\u002FEFM, and OVM – are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because these products do not meet all the criteria in 21 CFR 1271.10(a), and you do not qualify for any exception in 21 CFR 1271.15, these products are regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\n\nBe advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR 312]. None of your products are the subject of an approved BLA, nor is there an IND in effect for any of them. Based on our review, these products are unapproved new drugs that you are introducing or delivering for introduction into interstate commerce in violation of sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act and section 351(a)(1) of the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented significant deviations from current good tissue practice (CGTP) requirements, including deviations from 21 CFR 1271, for FVBM and OVM. Upon further review of information collected during the inspection, FDA also identified significant deviations from current good manufacturing practice (CGMP) requirements for VBM, CFM\u002FEFM, and OVM, including section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP requirements, your VBM, CFM\u002FEFM, and OVM drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)], your introduction or delivery for introduction into interstate commerce of these three drug products is a prohibited act.\n\nYour CGTP deviations for your FVBM and OVM products manufactured between January 2022 and June 2023, include, but are not limited to, the following:\n\n1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)]. For example, you failed to determine as ineligible (b)(4) deceased donors who have a documented medical diagnosis of sepsis. As discussed in the 2007 Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\u002FPs) (2007 DE Guidance), donor screening to reduce the risk of transmission of disease agents associated with sepsis is required. Tissues from these donors were manufactured into FVBM and OVM, and distributed for implantation into patients\u002Frecipients, some of which were associated with an outbreak of Mycobacterium tuberculosis infections. It appears this is a systemic issue not limited to these (b)(4) donors or products because this violation resulted from you following your SOP-0006 Donor Eligibility Determination Criteria, which does not require you to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, sepsis.\n\nWe have received and reviewed your written responses, dated October 14, 2023, and November 30, 2023, to FDA’s inspectional observations on the Form FDA-483. The corrective actions described in your response are not adequate to address the above noted violation that was on the FDA-483.\n\nIn your October response, you provided your revised procedure, SOP-006 Donor Eligibility Determination Criteria (as Attachment 2.2). Your “Donor Screening Guidance Document” in Attachment 2.2 and the revised sepsis algorithm in SOP-0006 do not determine as ineligible, donors who have a documented medical diagnosis of sepsis. Sepsis is a relevant communicable disease agent and disease (RCDAD) under 1271.3(r)(2), as described in the 2007 DE Guidance. Under 1271.75(d)(1), you must determine as ineligible a donor who is identified as having a risk factor for or clinical evidence of any RCDAD. You should revise Berkeley’s Donor Screening Guidance Document for sepsis and revise your sepsis algorithm in SOP-0006 so that these documents are compliant with 1271.75(d)(1).\n\nThis donor eligibility issue applies across your products, including those regulated solely under section 361 of the PHS Act. Based on information available to FDA, you have received tissues from at least (b)(4) donors who have sepsis documented in their medical records. We request that you provide us a list of all donors that have had risk factors for or clinical evidence of sepsis that you have determined to be eligible along with the products you have manufactured and distributed from these donors.\n\nYour CGMP deviations for VBM, CFM\u002FEFM, and OVM manufactured between January 2022 and June 2023, include, but are not limited to, the following:\n\n2. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example,\n\na. According to your Process Qualification Reports (dated January 17, 2017, March 16, 2020, and April 7, 2023), you only required (b)(4) donors to meet your process qualification acceptance criteria even if some donor batches in the validation\u002Fqualification failed to meet the criteria. For example, (b)(4) of (b)(4) OVM donor batches failed to meet your acceptance criteria, and (b)(4) of the (b)(4) donor batches failed to meet your acceptance criteria for sterility testing.\n\nb. You have not validated the manufacturing processes for VBM, CFM\u002FEFM, and OVM with respect to identity, strength, quality, and purity. Your Process Qualification Reports document product bioburden testing, sterility testing, environmental and personnel monitoring, and in some cases (b)(4) testing, as the only tests included in your acceptance criteria. These tests are inadequate to assure the identity, strength, quality, and purity of these products.\n\nBased on our review of the “retrospective validation addendums” you provided in your November 2023 response, you have not addressed the issues noted above. For example, your validations continue to focus on sterility assurance controls, rather than identity, strength, quality, and purity.\n\n3. Failure to have an adequate system necessary to prevent contamination or mix-ups during aseptic processing [21 CFR 211.42(c)(10)(iv)]. For example:\n\na. Your action limits for microbiological monitoring (i.e., active viable air and surface samples) within the critical area (i.e., inside the Biological Safety Cabinet (BSC)) were observed to be greater than (b)(4) colony forming units (CFUs). Such high numbers of microorganisms can contribute to product contamination and pose a potentially significant safety concern.\n\nb. You do not perform sampling of critical surfaces in the BSC for microorganisms in association with each production batch.\n\nc. Your personnel monitoring sample locations are inadequate for personnel performing aseptic processing. For example, your firm does not conduct personnel monitoring of the forearms\u002Fsleeves of operators working in the BSC where your products are aseptically processed.\n\n4. Failure to establish laboratory controls that include scientifically sound and appropriate specifications and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example:\n\na. You have not established scientifically sound and appropriate specifications and test procedures to assure that VBM, CFM\u002FEFM, and OVM conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing, which is inadequate to measure appropriate standards of identity, strength, quality, and purity.\n\nb. Sterility samples of VBM, CFM\u002FEFM, and OVM are frozen prior to sterility testing. Freezing product has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\n\nIn your responses, you have committed to stopping the manufacture and distribution of all viable bone matrix products until, you state, you have met, “FDA’s standards for tissue processing validation.” However, you have not addressed the products manufactured under the violative conditions described above that remain on the market and available for implantation nor have you addressed the above CGMP violations. We acknowledge that the above CGMP violations were not included in the FDA-483; we expect you to address them in response to this letter.\n\nAdditionally, your response fails to address your failure to have an IND in effect to study your VBM, CFM\u002FEFM, and OVM products or your lack of an approved BLA to lawfully market these products.\n\nPlease also be advised that FDA has conducted a preliminary review of your HCT\u002FP, Fiber Viable Bone Matrix (FVBM). Based on the limited information available to FDA, we do not have a basis at this time for concluding that the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271 are met for Berkeley Biologics’ FVBM allogeneic HCT\u002FP.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure that your establishment is in full compliance with applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you believe that your products are not in violation of the FD&C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion.\n\nYour response to this letter should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations - Division 2\n\ncc:\n\n(b)(6), (b)(7)(C)\n\n____________________\n\n1 We note that the product name was changed from Excel Fiber Matrix to Cellular Fiber Matrix on April 21, 2023.","Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.","berkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fberkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo","2026-10-26T08:08:03.464886+00:00","2024-08-27","Mesfin Mengesha","2026-08-19T23:52:08.617+00:00","OBPO 676984","2024-06-28",11,{"510k":240,"classification":241,"enforcement":242,"event":243,"event_backfill":244,"pma":245,"warning_letter":246},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]